Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (267 reviews)

For research use only. Not for use in humans.

Catalog No.S1047 Synonyms: MK0683

267 publications

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Selleck's Vorinostat (SAHA) has been cited by 267 publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )
Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )
Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )
J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )
Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )
Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )
EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )
BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )
Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )
J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MULLbY5ie2ViQYPzZZk>		MYSxJIg>	MnfNSG1UVw>?	MVzhcpRqNUiGQVOxJIFkfGm4aYT5JJdqfGhiSVO1NEBw\iByLkGxNkDPxE1?	MVGxNVk3ODR6OR?=
Friend leukemic cell	NVzXTYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL0N4p2PTBizszN	M2HQSFczKGh?	NWLVcVBETE2VTx?=	NX:0VG9sUUN3ME2wMlk6KM7:TR?=	NFXt[msyOjFyOUmxNy=>
K562	NYLRSlJCU2mwYYPlJGF{e2G7		NF;RUmE3KGh?	NGTtPGFFVVOR	M1;3emlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIfpeIghUUN3MDDv[kAxNjBzIN88US=>	NV\WcXIyOTJ2MUmzPFA>
HT1080	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUG3NkBp	MXjEUXNQ	MYHJR\|UxRTJwNDFOwG0>	NUDzXJpJOTJ{N{CxO\|U>
H1299	NGThV3pMcW6jc3WgRZN{[Xl?		NVK0S4VGOjBibXnu	M3naUmROW09?	Mnz6TY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	M1PTNlE1PTJzNEKy
H1299	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1LoVFczKGh?	NEnXUVZFVVOR	MkTiTWM2OD15LkK0JO69VQ>?	MXWxOFUzOTR{Mh?=
HeLa	M2SzTWtqdmG\|ZTDBd5NigQ>?		NV;QWXRnOzBibXnu		M{W4NWlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHjpd5RwdmViZHXhZ4V1gWyjc3Wge4l1cCCLQ{WwJI9nKDBwMkig{txO	NUO4VHBEOTV4MEO5OFk>
LOX-IMVI	NYf2fmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVK0PEBp		MVLJR\|UxRTFwMzFOwG0>	MWqxOVcyPTR5MB?=
NCI-H226	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVS0PEBp		M3rsd2lEPTB;Mj62JO69VQ>?	M3P3S\|E2PzF3NEew
RXF-631L	NW\jU4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml7DOFghcA>?		MWTJR\|UxRTJizszN	M4PzRVE2PzF3NEew
SNB-78	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnjyOFghcA>?		M4jhN2lEPTB;MU[g{txO	NFTU[FgyPTdzNUS3NC=>
St-4	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzrbm1MPDhiaB?=		M3zjfWlEPTB;NT6yJO69VQ>?	NWfuNmsyOTV5MUW0O\|A>
ARP1	NILEc4JHfW6ldHnvckBCe3OjeR?=	NV7abIl4OiEQvF2=	M2XhVVYhcA>?		NWW5V5JVUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NHrwSIgyPDd\|NEiwOi=>
CEM	M1XmdWtqdmG\|ZTDBd5NigQ>?		M2rPXVEhcA>?	NYjRc3pQTE2VTx?=	MoH5TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>?	MUOxOlQzODB4NB?=
HCT15	NFzNUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX20PEBp		M37YdWdKPTB;MD64NkDPxE1?	NWC2T2VqOTZ5MkOyNlc>
NCI-H23	NVS0b29ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDrbnY1QCCq		M4fPZWdKPTB;MD65NkDPxE1?	MlyyNVY4OjN{Mke=
GM15850	NFvGPYJMcW6jc3WgRZN{[Xl?	NWDXZYlHOi53IN88US=>	MVu5OkBp	Mnu0SG1UVw>?	MnjiTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEG0JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MkjUNVY6OjF\|Nke=
GM15850	MlfFT4lv[XOnIFHzd4F6	NI\mXVAzNjVizszN	M2PUU\|k3KGh?	NGHGTY9FVVOR	NInCSlZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NETqTJYyPjl{MUO2Oy=>
GM15850	M3vFXmtqdmG\|ZTDBd5NigQ>?	Mm\KNk42KM7:TR?=	MlSxPVYhcA>?	MYXEUXNQ	M2LabWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxNkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NYq2UXpqOTZ7MkGzOlc>
GM15850	NELt[5RMcW6jc3WgRZN{[Xl?	M{TSVVIvPSEQvF2=	NEDUSHc6PiCq	MWXEUXNQ	NFey[JVKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NWD2d\|BrOTZ7MkGzOlc>
GM15850	NGPhTXdMcW6jc3WgRZN{[Xl?	M3\TO\|IvPSEQvF2=	NGrHcmo6PiCq	M3LydGROW09?	MXzJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NWnTWZU{OTZ7MkGzOlc>
GM15850	NUS3S\|hLU2mwYYPlJGF{e2G7	MWOyMlUh\|ryP	MWq5OkBp	MXLEUXNQ	NHHyXZZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M2ntTlE3QTJzM{[3
U937	NUnNPFQ5TnWwY4Tpc44hSXO\|YYm=	NInhUHQ2KM7:TR?=	NGfvTGUzPCCq	MVPEUXNQ	NEfYRotE\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn	MmDQNVcxODR5MUi=
H661	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1qyPFQ5KGh?		NWLUUGlLUUN3ME2xJO69VQ>?	MlLKNVcyPTdyMEm=
U937	MWrGeY5kfGmxbjDBd5NigQ>?	NHS1Sm02KM7:TR?=	MUKyOEBp	NHf3OYtFVVOR	MUnJcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	NIPZPHEyPzR2N{e1NC=>
U937	NHPFUIRHfW6ldHnvckBCe3OjeR?=	MXOxJO69VQ>?	MWCyOEBp	MlfQSG1UVw>?	MWHF[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NEHJbpkyPzR2N{e1NC=>
RAW264.7	NV:wZZZVTnWwY4Tpc44hSXO\|YYm=	M4rUT\|ExKM7:TR?=	NFrnU4EzPGh?	NFXW[mx4[XSnch?=	MV3Jcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR\|UxKG:oIECuO\|Yh\|ryP	Mm\vNVc1Pzd3MUi=
RAW264.7	MULGeY5kfGmxbjDBd5NigQ>?	NFTsO5QyOCEQvF2=	M2LTWlI1cA>?	NFvvNG94[XSnch?=	NVHlOGt4UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iBzLki4JO69VQ>?	NIHKN4YyPzR5N{WxPC=>
SC9	NYnITnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfhVpE1QCCq		MlPITWM2OD1yLk[wOkDPxE1?	NU\zRnB5OTd3MEeyNVk>
ST14A	MUHGeY5kfGmxbjDBd5NigQ>?	M{\OblUhdk1?	NVLjZ2o4PzJiaB?=		NI[3U3BKdmO{ZXHz[UBqdiCURWPUM25TW0ZibWLORUBmgHC{ZYPzbY9v	NVy4Z2NrOTd3NkW5PVM>
ST14A	M1i0[mZ2dmO2aX;uJGF{e2G7	MWS1JI5O	MXi3NkBp		M1T6OGlv[3KnYYPlJIlvKEV{RkGgcXJPSSCneIDy[ZN{cW:w	NFLxXWMyPzV4NUm5Ny=>
PANC1	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rTflEh\|ryP			NWG3NmNvUUN3ME2wMlQ2KM7:TR?=	MmXyNVc2QDh5NES=
PANC1	M2m1[WZ2dmO2aX;uJGF{e2G7	M1zhV\|Eh\|ryP	MWCyOEBp		MlzQTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	Mn\PNVc2QDh5NES=
PANC1	NHfmZ4tHfW6ldHnvckBCe3OjeR?=	MnzaNUDPxE1?	M2XleVI1KGh?		NIPDZ\|dKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	NEjwXJkyPzV6OEe0OC=>
PT45	M{jpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zwfmlEPTB;NDFOwG0>	NILWWokyPzV6OEe0OC=>
ACHN	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3nGWlIyKGh?		M2fadGdKPTB;MD62OUDPxE1?	NV\3WoRTOTd4NkK2NFY>
PC3	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYriTm5MOjFiaB?=		NIn4OJlIUTVyPUCuO\|Eh\|ryP	MYexO\|Y3OjZyNh?=
A431	MWLDfZRwfG:6aXOgRZN{[Xl?		NH\yXWg4OiCq		NFvKW2RKSzVyPUSuNkDPxE1?	NFfqcZoyPzZ7MUe2Ny=>
Cal27	NEjOWldEgXSxdH;4bYMhSXO\|YYm=		MlTqO\|IhcA>?		NETpV\|ZKSzVyPUOuNkDPxE1?	NXP5e3dpOTd4OUG3OlM>
CCRF-CEM	MXPDfZRwfG:6aXOgRZN{[Xl?		MWC3NkBp		MXXJR\|UxRTBwODFOwG0>	M1zZR\|E4PjlzN{[z
EOL1	NU\5SmpNS3m2b4TvfIlkKEG\|c3H5		M4nJdlczKGh?		NGrIcopKSzVyPUGg{txO	MX[xO\|Y6OTd4Mx?=
Hec-1-A	MoTTR5l1d3SxeHnjJGF{e2G7		MYe3NkBp		NXHnOndvUUN3ME2xJO69VQ>?	NYHZfHBvOTd4OUG3OlM>
HeLa	NGT4UYdMcW6jc3WgRZN{[Xl?	NVm5c5hiOTBizszN	Mm\qN\|AhdWmw	NGrQU25FVVOR	M{TSfWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzFid3n0bEBKSzVyIH;mJFAvODJizszN	NXKx[m5LOTd4OUG3OlM>
RKOp21	NH3WRVBEgXSxdH;4bYMhSXO\|YYm=		NGPr[os4OiCq		Ml;1TWM2OD1zLke2JO69VQ>?	NXTUfYI3OTd4OUG3OlM>
Saos2	M1WxZmN6fG:2b4jpZ{BCe3OjeR?=		MUS3NkBp		MVTJR\|UxRTJwMzFOwG0>	M4LWV\|E4PjlzN{[z
SK-OV-3	MWTDfZRwfG:6aXOgRZN{[Xl?		MljPO\|IhcA>?		MUXJR\|UxRTJwMjFOwG0>	NWHEVGZ7OTd4OUG3OlM>
U87MG	M1Sx[GN6fG:2b4jpZ{BCe3OjeR?=		M4\nNFczKGh?		NELtUZVKSzVyPUGxJO69VQ>?	MV[xO\|Y6OTd4Mx?=
NUGC3	M2jYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXYfYFbPSEQvF2=	NXHTfWVlOjRiaB?=		NHzTc5RIUTVyPUKuO\|kh\|ryP	Mn3iNVc6ODR6NEO=
CCD1059SK	M376NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnEWmQ6UUN3ME20N{42KM7:TR?=	NEm1VnAyQDJ2N{W1OC=>
HepG2	NFLufXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7oWZVUUUN3ME2wMlAxODZizszN	MlTCNVgzPDd3NUS=
HT1080	MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\pbWlEPTB;MD6wNFI1KM7:TR?=	NY[1U4ZTOTh{NEe1OVQ>
SKBR3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDTTWM2OD1yLkig{txO	MnHrNVgzPDd3NUS=
SNB78	M3viTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;FR\|UxRTF4IN88US=>	NX3NO4ZyOTh{NEe1OVQ>
SQ20B	M3vOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTNizszN	NVvyeJpuOTh{NEe1OVQ>
St4	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXQd5JGSzVyPUWuNkDPxE1?	M3r1ZlE5OjR5NUW0
MCF7	MV;GeY5kfGmxbjDBd5NigQ>?	M{\xPVExKM7:TR?=	MkfEPEBp	NFvpc5RFVVOR	NF7hWnBKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	M2jVUVE5OjZ7MkK2
HEK293	MnP1T4lv[XOnIFHzd4F6		MoXlNUBp	M{DBdmROW09?	MnzSTY5pcWKrdHnvckBw\iCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6wN{DPxE1?	MY[xPFMxQDV4Mx?=
HEK293	NFTiTnBMcW6jc3WgRZN{[Xl?		M{\NVFEhcA>?	MnHUSG1UVw>?	NU\lSJEzUW6qaXLpeIlwdiCxZjDISGFEOyC5aYToJGlEPTBib3[gNE4xPTdizszN	M{KxflE5OzB6NU[z
G401	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVq3NkBp	M4jWSGROW09?	Mn3vTWM2OD1zIN88US=>	MoTTNVg{PzB\|N{O=
HeLa	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3e2T\|czKGh?	M{\wNWROW09?	M{\TeGlEPTB;MD60OkDPxE1?	M33aSlE5OzdyM{ez
Human renal epithelial cell	M1r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp	NFXHRpRFVVOR	Mn\RTWM2OD1zNDFOwG0>	NUDGfpR[OTh\|N{CzO\|M>
U937	NUL4TWxPTnWwY4Tpc44hSXO\|YYm=	MUS1JO69VQ>?	MWGyOEBp		MnHmTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?	NX72WGN6OTh\|OEGyN\|g>
U937	NEXIc\|dHfW6ldHnvckBCe3OjeR?=	MUW1JO69VQ>?	NG[1dpQzPCCq		MWnJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w	MWOxPFM5OTJ\|OB?=
U937	NHHTR2NHfW6ldHnvckBCe3OjeR?=	Mn;FOUDPxE1?	NEC0dIozPCCq		NFPUOm1KdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44>	NV;vTJN{OTh\|OEGyN\|g>
U937	NUjmTWhETnWwY4Tpc44hSXO\|YYm=	MmHCOUDPxE1?	NX7nW\|IxOjRiaB?=		M3mwdWlv\HWldHnvckBw\iCjcH;weI9{cXN?	M4HWZ\|E5OzhzMkO4
U937	NGTXfHZHfW6ldHnvckBCe3OjeR?=	MoTvOUDPxE1?	NGXRV\|YzPCCq		MXnJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>?	NXS5fJR3OTh\|OEGyN\|g>
U937	M1Kz[2tqdmG\|ZTDBd5NigQ>?	M4ridlUh\|ryP	M1LE[FI1KGh?		NVu1cnRnUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	MlnNNVg{QDF{M{i=
U937	NYPkeppMU2mwYYPlJGF{e2G7	MVG1JO69VQ>?	MYiyOEBp		MkjRTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNB?=	MmjZNVg{QDF{M{i=
HEK-TE	NEG5W\|RHfW6ldHnvckBCe3OjeR?=	NF\nWlY2KM7:TR?=	NVLuOXZ7Pmh?	MYXEUXNQ	MoHsTY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	NYTHcFBPOTh2M{SxOFQ>
HPDE6c7	MVLDfZRwfG:6aXOgRZN{[Xl?	NYq3bXBvPTBizszN	NVGyWoF5PzJiaB?=	Mm\PSG1UVw>?	MXTJR\|UxRTFwMzFOwG0>	NFmwXWwyQDR7NES2Ny=>
Human microvascular epithelial cell	NFLlUnFEgXSxdH;4bYMhSXO\|YYm=	NIHpW5U2OCEQvF2=	M3LHOVczKGh?	NFz4e5VFVVOR	M13oXGlEPTB;MT6zJO69VQ>?	MoPENVg1QTR2NkO=
Hup T3	M3HmfmN6fG:2b4jpZ{BCe3OjeR?=	M1\YeVUxKM7:TR?=	MXe3Nog>	MX7EUXNQ	MUnJR\|UxRTBwODFOwG0>	MofZNVg1QTR2NkO=
Mia Paca2	M334NWN6fG:2b4jpZ{BCe3OjeR?=	MnKxOVAh\|ryP	NWjnN2g5PzKq	NY[5eXJ3TE2VTx?=	NF\ic45KSzVyPUGuNUDPxE1?	MX:xPFQ6PDR4Mx?=
Panc 04.03	NUHLWml1S3m2b4TvfIlkKEG\|c3H5	MXK1NEDPxE1?	NEHsTIU4Omh?	MVnEUXNQ	MWfJR\|UxRTFwMjFOwG0>	NYG3WnhHOTh2OUS0OlM>
SU 86.86	NX3BfXhiS3m2b4TvfIlkKEG\|c3H5	NWf6UG1RPTBizszN	M{[w[VczcA>?	NYWxUGhYTE2VTx?=	MV3JR\|UxRTFwMzFOwG0>	MmXxNVg1QTR2NkO=
HEK293	MYTLbY5ie2ViQYPzZZk>		M{LUdFMhcA>?		MWXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	MorCNVg2PTh4Nkm=
HeLa	M2PjPWtqdmG\|ZTDBd5NigQ>?		NFnLcmQzKGh?		NVjp[VZRUW6qaXLpeIlwdiCxZjDueYNt\WG{IFjERWMhf2m2aDDJR\|UxKG:oIECuNFg{KM7:TR?=	NHOwfo0yQDV3OE[2PS=>
RAW264.7	NFy1[mxHfW6ldHnvckBCe3OjeR?=	MWKyJO69VQ>?	NHvHNoM{NjViaB?=	MorSSG1UVw>?	MV\BcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN	M{nOUlE5PjR2OU[5
NB4			NGjV[3Q1QGh?	M{TPdGROW09?	NXjuWFhWUUN3ME2wMlYh\|ryP	NIq3Z\|QyQDd{M{O0PS=>
HEK293	M4nHbGZ2dmO2aX;uJGF{e2G7	Mn\QNVAh\|ryP	NGjieXEzPCCq	NWHHb\|BFTE2VTx?=	MlnvRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	NUnsZXZMOTlyMkK2O\|U>
HCT116	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXTOSYxiPzKq	NIjMV3ZFVVOR	MmPKTWM2OD1yLkOxJO69VQ>?	NIKweoYyQTB6NEK5OC=>
HeLa	Mnz5T4lv[XOnIFHzd4F6	MmGyNkDPxE1?	MXqzNEBucW5?	NVTkZVZFTE2VTx?=	M3PNbWlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	MXuxPVA5PDJ7NB?=
IGROV1	M4Hib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUf3cJZRPzJiaB?=	NFfXPYVFVVOR	MnvYTWM2OD1{LkKg{txO	NV;rV4E4OTlyOESyPVQ>
IGROV1	M2L0VmtqdmG\|ZTDBd5NigQ>?	MnTtOUDPxE1?	NIrZfFczPCCq	NID4OGRFVVOR	NWDmfHQ5UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIC1N{Bi[2W2eXzheIlwdg>?	MmHGNVkxQDR{OUS=
IGROV1	MWLLbY5ie2ViQYPzZZk>	MnvmNVAh\|ryP	MV:0JIg>	NI\uVpZFVVOR	NHfXRZJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	MVGxPVA5PDJ7NB?=
IGROV1	Ml73T4lv[XOnIFHzd4F6	M4W4SFExKM7:TR?=	NGXJO5E1KGh?	MUDEUXNQ	NYrOSGh5UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	M1jtS\|E6ODh2Mkm0
T24	NE\mW4JMcW6jc3WgRZN{[Xl?		NHzkU2E{KGh?		MnraTY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMUKg{txO	M1r3[VE6ODh2M{m1
T24	Ml3HT4lv[XOnIFHzd4F6		MkfIN{Bp		MmTxTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNlUh\|ryP	MlziNVkxQDR\|OUW=
HeLa	MXLLbY5ie2ViQYPzZZk>		MlHhNVUhdWmw	NVfHdppkTE2VTx?=	MlrGTY5pcWKrdHnvckBw\iCKRFHDOkBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNE4xQDV3IN88US=>	NUTEXIVPOTlyOUO4PFQ>
HeLa	NHfMPIJMcW6jc3WgRZN{[Xl?		NVfwR3lqOTVibXnu	MVPEUXNQ	M2OwbGlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	NV\DbVdYOTlyOUO4PFQ>
NCI-H69	NInEXGpEgXSxdH;4bYMhSXO\|YYm=		M{niOVczKGh?	NFLVVmxFVVOR	M4XPfGlEPTB;Mj6wOkDPxE1?	MVixPVA6Ozh6NB?=
SKMES1	MmLkR5l1d3SxeHnjJGF{e2G7		MnW3O\|IhcA>?	MnXtSG1UVw>?	NETCToVKSzVyPUKuOFIh\|ryP	MmXENVkxQTN6OES=
S2	NY\Ke2tXU2mwYYPlJGF{e2G7	M2Trc\|AvOS1zMDFOwG0>	NHrxZZEyKGh?		NWDPVlJCUW6qaXLpeIlwdiCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0hUESDQ{Gg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkC1PUDPxE1?	MXGxPVMyPzR3MB?=
SHSY5Y	M2rXbGtqdmG\|ZTDBd5NigQ>?	MnLQNVAh\|ryP	NF3qZWQ1QCCq	MVzEUXNQ	NEexcIRKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOUDPxE1?	Mlz2NVk{PDRzN{W=
SHSY5Y	M17mOWN6fG:2b4jpZ{BCe3OjeR?=	MXqxNEDPxE1?	MWO0PEBp	M332NWROW09?	MlTGTWM2OD1{IN88US=>	MYGxPVM1PDF5NR?=
DMS114	MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPoZoM1QCCq		MUXHTVUxRTJwOTFOwG0>	NHXUblkyQTRzOUKwOS=>
HBC5	NGHYbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnS5OFghcA>?		MWjHTVUxRTF5IN88US=>	M2jZc\|E6PDF7MkC1
SNB78	NVn3XHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mon5OFghcA>?		MoDPS2k2OD1zNjFOwG0>	M2XCflE6PDF7MkC1
HeLa	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVW3NkBp	MnrxSG1UVw>?	NFWxPZlKSzVyPUCuOFYh\|ryP	NF3jWpkyQTR2MUi0Oi=>
BHK	MVzLbY5ie2ViQYPzZZk>	NX2wendqPSEQvF2=	M3PMZVI1KGh?	NVfyTnhYTE2VTx?=	NUXEeWxTUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NG\VRVAyQTl4Nke4PS=>
CFBE41o-	M2DM[mtqdmG\|ZTDBd5NigQ>?	NYXSeZJEPSEQvF2=	MUS4JIg>	NF7XemJFVVOR	MWjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|	NFzW[GYyQTl4Nke4PS=>
CFBE41o-	MnLST4lv[XOnIFHzd4F6	MlnuOUDPxE1?	NVfvcpo4PCCq	NV:wUmJXTE2VTx?=	M3L3VmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBt\X[nbB?=	NESxTpIyQTl4Nke4PS=>
CFBE41o-	MUjLbY5ie2ViQYPzZZk>	M2\MPFEh\|ryP	M3zJc\|EhcA>?	M1ezWWROW09?	NEjIXWZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gR2ZVWiCycn;0[YlvKGyndnXs	NVTpZYxROTl7Nk[3PFk>
Primary bronchial epithelial cell	MlniT4lv[XOnIFHzd4F6	MWqxJO69VQ>?	M4XGO\|I1KGh?	Mnf0SG1UVw>?	MlnKTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	NVP6PGl1OTl7Nk[3PFk>
CFBE41o-	NETCcVNMcW6jc3WgRZN{[Xl?	MXKxJO69VQ>?	NXPscVBLPSCmYYnz	Mne3SG1UVw>?	NV7TSHJJUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	M{K2cFE6QTZ4N{i5
CFBE41o-	MVfLbY5ie2ViQYPzZZk>	Ml7iNUDPxE1?	MYOyOEBp	NFm1d4JFVVOR	M1PDR2lvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?=	NIjsRVgyQTl4Nke4PS=>
CFBE41o-	Mo\sT4lv[XOnIFHzd4F6	MYq1JO69VQ>?	MlHpNlQhcA>?	NHrmVYxFVVOR	MUTJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIILheIUhd2ZibXH0eZJifGmxbjDv[kBETlSUIIDyc5RmcW5idH:gbZR{KGeueXPv[o9zdQ>?	NH7TeGgyQTl4Nke4PS=>
CFBE41o-	M{P5cGtqdmG\|ZTDBd5NigQ>?	NGn0dXY2KM7:TR?=	MVWyOEBp	MnrMSG1UVw>?	NITGOJdKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu	MmHiNVk6PjZ5OEm=
CFBE41o-	NIHFbXZMcW6jc3WgRZN{[Xl?	M1rqXlUh\|ryP	MkfpNlQhcA>?	MYXEUXNQ	NVnzWVdjUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju	NF3nT5cyQTl4Nke4PS=>
Primary bronchial epithelial cell	NYXvVYNEU2mwYYPlJGF{e2G7	NHHVcIY2KM7:TR?=	MmXtNlQhcA>?	NVnycYlWTE2VTx?=	NHLWTmdKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	NHfaR5YyQTl4Nke4PS=>
Primary bronchial epithelial cell	NW\nOoNjU2mwYYPlJGF{e2G7	MVWxJO69VQ>?	NV:0XXpZQTZiaB?=	M1\nVmROW09?	NH7YOYxKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN?	MlLaNVk6PjZ5OEm=
BxPC3	NH2xUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVS3NkBp		M4LXemlEPTB;Mj63JO69VQ>?	MmrONlAyPDN5N{i=
CAL27	NVzKWGFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml:xO\|IhcA>?		Mo\MTWM2OD1\|LkeyJO69VQ>?	NFLrb2EzODF2M{e3PC=>
Capan1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX;vV4diPzJiaB?=		NHX4fGJKSzVyPUeuN{DPxE1?	MXyyNFE1Ozd5OB?=
HCC827	NFfLXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3jWb\|czKGh?		MlH3TWM2OD1zLkig{txO	MmTqNlAyPDN5N{i=
LNCAP	M1f0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1G3XFczKGh?		M4rNZWlEPTB;MD61PEDPxE1?	NWfOR4plOjBzNEO3O\|g>
NCI-H2122	M12yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3jkfFczKGh?		NVjmVYxJUUN3ME23MlUh\|ryP	M{jHNlIxOTR\|N{e4
NCI-H358	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHHtZ4o4OiCq		M1TUV2lEPTB;Mj61JO69VQ>?	NFj3eWozODF2M{e3PC=>
SCC15	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHvTTos4OiCq		NH;ufVdKSzVyPUKuOFkh\|ryP	NGHKfmkzODF2M{e3PC=>
SCC25	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUW3NkBp		NXy3W3BLUUN3ME2xMlk{KM7:TR?=	NYi2T5pEOjBzNEO3O\|g>
SKHEP1	NXq2T\|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYG3NkBp		NHjEPJFKSzVyPUOuOFYh\|ryP	M13z[FIxOTR\|N{e4
BJ	M3zLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHKfoptOTByIN88US=>	MYe0PEBp	M2XRfmROW09?	NF3UbHZIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	MWGyNFE1Ozh2MB?=
MUF	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLjeG1mOTByIN88US=>	M1u3flQ5KGh?	NYn5UIw5TE2VTx?=	NHTsWlVIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	NFjmfGkzODF2M{i0NC=>
Caco-2	M2\jeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLRPGprOTByIN88US=>	M1jnOVQ5cA>?	M2HwXmROW09?	M3mxcmlEPTB;OD6xJO69VQ>?	NVLSeVRxOjBzNEO4OFA>
Caco-2	NVm2cVd2U2mwYYPlJGF{e2G7	NHm4dGY2KM7:TR?=	M3vFUFQhcA>?	M3\HTWROW09?	MnLyTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvckBKSzVyIH;mJFAvODN5IN88US=>	NF\5VFYzODF2M{i0NC=>
Caco-2	M1O1NmtqdmG\|ZTDBd5NigQ>?	NV3IeFZzOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MnTCOEBp	MXrEUXNQ	NVLwN4Z{TXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJJdqfGhiSVO1NEBw\iByLkGxPUDPxE1?	NYXQ[IVbOjBzNEO4OFA>
Caco-2	NU\BTFduU2mwYYPlJGF{e2G7	NVrIT2tOOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MWS0JIg>	M{fDO2ROW09?	M3LqOGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMzD3bZRpKEmFNUCgc4YhOC5zNEeg{txO	NEL6UokzODF2M{i0NC=>
Caco-2	MknjT4lv[XOnIFHzd4F6	MoPiOk4{OiCwTTD0c{A3OzJizszN	MWK0JIg>	NXOw[Xh7TE2VTx?=	NGfrPXZGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Wge4l1cCCLQ{WwJI9nKDF{Lk[g{txO	NIrXTo0zODF2M{i0NC=>
Caco-2	M2r3fGtqdmG\|ZTDBd5NigQ>?	MWS2MlMzKG6PIITvJFY{OiEQvF2=	M4WyZlQhcA>?	M4jVVGROW09?	NGH3OWlGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{ege4l1cCCLQ{WwJI9nKDRzIN88US=>	NYC1fpNFOjBzNEO4OFA>
Caco-2	MmmwT4lv[XOnIFHzd4F6	MlnmNE4{OTZibl2geI8hOzFwNjFOwG0>	M{P2PFQhcA>?	M4\pVWROW09?	MknlSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN4	NITJO28zODF2M{i0NC=>
HepG2	NIH1cpdMcW6jc3WgRZN{[Xl?	M4XpO\|Uh\|ryP	MnruOog>	NFzWZ2JFVVOR	MUDJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	MkXYNlAyPDN6NEC=
HepG2	MXzLbY5ie2ViQYPzZZk>	MmHZOUDPxE1?	NXjxWJRGPmh?	MUnEUXNQ	NWnEV2s5UW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;u	NULCPFBvOjBzNEO4OFA>
HepG2	MYrLbY5ie2ViQYPzZZk>	M{DH[\|Uh\|ryP	M1PEZVZp	M4PkSmROW09?	NYH3XIhGUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	M3\oTlIxOTR\|OESw
HepG2	MmTzT4lv[XOnIFHzd4F6	NX\wWG5GPSEQvF2=	MlHrOog>	MYrEUXNQ	M3;ETWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	MXGyNFE1Ozh2MB?=
COLO205	NVy2dIdYU2mwYYPlJGF{e2G7	M1v3NFExKM7:TR?=	MWSyOEBp	MlrsSG1UVw>?	M3y0OGlvcGmkaYTpc44hd2ZiSFTBR\|Eh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25id3n0bEBKSzVyIH;mJFIvOiEQvF2=	NFLjT5kzODR3MUO3PC=>
SCC4	NFLZbndMcW6jc3WgRZN{[Xl?	NETOU2QyKM7:TR?=	MV6yOIg>		MlnSTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	NWnTdYNQOjB2NUKyNlU>
SCC4	NXXFb2VyU2mwYYPlJGF{e2G7	MVSxJO69VQ>?	NXW3[pFtOjSq		NGWwTmNKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	NVXlfmdWOjB2NUKyNlU>
SCC4	Ml;QSpVv[3Srb36gRZN{[Xl?	M2PRW\|Eh\|ryP	NGXvemM2KG2rbh?=		MoG3RYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	M17ROlIxPDV{MkK1
NB4	NVLP[mhMTnWwY4Tpc44hSXO\|YYm=	M{DOfFUh\|ryP	NVvYbHR4OjRiaB?=	NUPTZoNrTE2VTx?=	MVLD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn	M1\ReFIxPDlzNESw
NB4	M1XCVWtqdmG\|ZTDBd5NigQ>?	NVvrdXJ2PSEQvF2=	NX7peFNyOjRiaB?=	M{HqemROW09?	M1;YS2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	MVyyNFQ6OTR2MB?=
NB4	M1PoU2Z2dmO2aX;uJGF{e2G7	MVi1JO69VQ>?	NYHkXHRKOjRiaB?=	NF\ySmZFVVOR	NXLHZ4x[UW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v	NEHNOHYzODR7MUS0NC=>
NB4	M3LaWmtqdmG\|ZTDBd5NigQ>?	MVW1JO69VQ>?	NUjmTpVHOjRiaB?=	NGnyWFFFVVOR	NXL5TWUyUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMh[WOndInsZZRqd25?	MnrBNlA1QTF2NEC=
NUGC3	NI\hSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrHTVUxRTJwOUSg{txO	NGLiO\|kzODh3MEm3NS=>
A549	NEHXVVZHfW6ldHnvckBCe3OjeR?=	NHOxUnc2KM7:TR?=	NIPhSWw{KGh?	M3jNTWROW09?	Mkm3TY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	MkjpNlA5PTV{MEi=
HUT78	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXi3NkBp	NU\5S\|VUTE2VTx?=	M1jwOmdKPTB;MD6zJO69VQ>?	NXr3fWU5OjB6OESyNFg>
U937	NHvPbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBp	MnKxSG1UVw>?	NIrQO2hIUTVyPUCuN\|kh\|ryP	M1P5R\|IxQDh2MkC4
A431	MlnER5l1d3SxeHnjJGF{e2G7		MoTOO\|IhcA>?		NGO5TndEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFQvOiEQvF2=	NF\zblczOTB6ME[yPS=>
A549	NFiyfpdEgXSxdH;4bYMhSXO\|YYm=		MmO4O\|IhcA>?		NWXwfGVnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	NHr1[YkzOTB6ME[yPS=>
CAL27	M164ZmN6fG:2b4jpZ{BCe3OjeR?=		MUm3NkBp		MlO3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2FNOjdiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gN{4zKM7:TR?=	NXjwNGRiOjFyOEC2Nlk>
HeLa	MYDDfZRwfG:6aXOgRZN{[Xl?		M1rEN\|czKGh?		NYTFbJA5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjVizszN	NVS4bHJbOjFyOEC2Nlk>
Sf21	NF65NGNMcW6jc3WgRZN{[Xl?		NFOyZ20{KGh?		M4LoZWlvcGmkaYTpc44hd2ZiRnzh[{B1[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzhiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjJizszN	NHTXTlAzOTB6ME[yPS=>
SKBR3	M4njdWN6fG:2b4jpZ{BCe3OjeR?=		MYC3NkBp		MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlYh\|ryP	NG\MTpozOTB6ME[yPS=>
SKOV3	MXvDfZRwfG:6aXOgRZN{[Xl?		MmDBO\|IhcA>?		NUKwU5FES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NHfMNmgzOTB6ME[yPS=>
COR-L23	M1;5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3e0bFExKM7:TR?=	NWrxOoV5PzJiaB?=	NEDqXWlFVVOR	MYPHTVUxRTFwMTFOwG0>	MVWyNVA5ODZ2Nx?=
DU145	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfK[nVDOTBizszN	MnLUO\|IhcA>?	MlXvSG1UVw>?	NETWS\|RIUTVyPUGuNFUh\|ryP	MmftNlExQDB4NEe=
LoVo	NF3oZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUGxNEDPxE1?	NV3YNGxsPzJiaB?=	MnHwSG1UVw>?	NXTEUopyT0l3ME2xMlch\|ryP	NYHxWVBiOjFyOEC2OFc>
MCR5-SV2	NWjwWodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	NWrD[YRIPzJiaB?=	M4DkPWROW09?	MmnxS2k2OD1{LkGg{txO	NEjFW\|YzOTB6ME[0Oy=>
HCT116	MUnLbY5ie2ViQYPzZZk>	MX2zNEDPxE1?	NGDDboU{OCCq	MWrEUXNQ	M3rjO2lvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36=	NF[xbI4zOTB6ME[0Oy=>
HCT116	M{LLcGtqdmG\|ZTDBd5NigQ>?	NX3UNlZKOzBizszN	MkjJN\|AhcA>?	NFrnWpBFVVOR	NV\kWZJTUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	MWWyNVA5ODZ2Nx?=
U937	MVfLbY5ie2ViQYPzZZk>	NGHqc5I2KM7:TR?=	M2SwVlI1KGh?	M3X1SmROW09?	MmrXTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl?	MWeyNVI6OjR7Mh?=
U937	M2T5V2tqdmG\|ZTDBd5NigQ>?	MoTaOUDPxE1?	MWiyOEBp	NEPZZ5FFVVOR	M{Tr[WlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEtzOB?=	M3nXbVIyOjl{NEmy
U937	NIrGd3BMcW6jc3WgRZN{[Xl?	NFXhOpI2KM7:TR?=	MYOyOEBp	NVu4eGxwTE2VTx?=	MYnJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	M132flIyOjl{NEmy
U937	NYLhemZWU2mwYYPlJGF{e2G7	NF;3dHY2KM7:TR?=	NXW3TItrOTVibXnu	MknGSG1UVw>?	MkXOTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw>	NXjkcm1IOjF{OUK0PVI>
A2780	NHWxepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWS5OkBp	NICxTmlFVVOR	M3jzfWlEPTB;MT62NkDPxE1?	M1G2O\|IyPjN2NEOw
COLO205	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{XHd\|k3KGh?	NHvXSopFVVOR	MULJR\|UxRTJwMUKg{txO	MnHwNlE3OzR2M{C=
Hep3B	NHzBSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoDaOFghcA>?	M1KyZWROW09?	NE\hN5JIUTVyPUGuNlEh\|ryP	M1TqTFIyPzF{MUS2
GM11272	MmrESpVv[3Srb36gRZN{[Xl?	NVvXZ21yOTByIH7N	NULZNph4PzJiaB?=	NVjNeGZbTE2VTx?=	NIfwPI5T\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	M3zufVIyQDRyN{G2
CFBE41o	MYjLbY5ie2ViQYPzZZk>	NIjTTW42KM7:TR?=		MkK4SG1UVw>?	MUjEc5dvKHKnZ4XsZZRqd25ib3[gTGRCSzdiYYSgNE4zKHSxIEWgeW0>	MXeyNVk5PDl3OB?=
CFBE41o	MVPGeY5kfGmxbjDBd5NigQ>?	NF7zNnEyKM7:TR?=	MmK3NlQhcA>?	MVXEUXNQ	MmH3VoV{fG:{YYTpc44hd2ZiQ1\UVkBl\Wy2YV[1NFghdXW2YX70JJRz[W[oaXPrbY5oKHSxIHPlcIwhe3W{ZnHj[UBieyCpbInjc4Zwem2\|	MYmyNVk5PDl3OB?=
DU145	Mk\yT4lv[XOnIFHzd4F6	NGjyZo4zNjVizszN	M1T4U\|I1KGh?	NHu4eW1FVVOR	MnHuTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjG5YX[xJJBzd3SnaX6g[ZhxemW\|c3nvci=>	M2XQWFIzOjZyMU[2
DU145	NUeyd4VKU2mwYYPlJGF{e2G7	NGS3cnM2KM7:TR?=	Mn;mNlQhcA>?	NHjPZVJFVVOR	NUHlOFB4UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSESgZYNmfHmuYYTpc44>	Mnz0NlIzPjBzNk[=
DU145	M4TDVGtqdmG\|ZTDBd5NigQ>?	M1e3VlUh\|ryP	MUGyOEBp	NFnJVFNFVVOR	M3nCTWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHj5dIVz[WOndInsZZRqd25?	MkLINlIzPjBzNk[=
786-0	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HnV\|YvOiEQvF2=	NGjJbII4OiCq	MojqSG1UVw>?	NHOybZBIUTVyPUOuNkDPxE1?	M4LxfFIzPDN3Nk[5
A498	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjHXJdOPi5{IN88US=>	MonWO\|IhcA>?	M3PYPGROW09?	NUnrW49zT0l3ME2xMlYh\|ryP	NHfCd4ozOjR\|NU[2PS=>
A549/ATCC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7EOk4zKM7:TR?=	Mkn6O\|IhcA>?	NFLmUolFVVOR	NFnxRXJIUTVyPUGuOkDPxE1?	MmHtNlI1OzV4Nkm=
ACHN	M{nyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\5OmE3NjJizszN	MX23NkBp	NWeycJo{TE2VTx?=	M4L0PWdKPTB;MT6zJO69VQ>?	NHOyfZUzOjR\|NU[2PS=>
BT549	NXn3UnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFy5S\|c3NjJizszN	MknKO\|IhcA>?	NXizd3VYTE2VTx?=	NH3ieVhIUTVyPUGuN{DPxE1?	MVSyNlQ{PTZ4OR?=
EKVX	NGP3fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nWbVYvOiEQvF2=	NWPNcGtFPzJiaB?=	MXTEUXNQ	MnPnS2k2OD1zLkOg{txO	MXqyNlQ{PTZ4OR?=
HCT15	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS2T\|FxPi5{IN88US=>	MnnaO\|IhcA>?	M3zk[mROW09?	NWPmTVNNT0l3ME2yMlUh\|ryP	NWr4WlNMOjJ2M{W2Olk>
HOP92	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\sVHc3NjJizszN	NGe0Umo4OiCq	NIPET5NFVVOR	MWHHTVUxRTRizszN	MUOyNlQ{PTZ4OR?=
IGROV1	M{XH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L6flYvOiEQvF2=	NI\tN2Q4OiCq	MmnpSG1UVw>?	MXvHTVUxRTFwMzFOwG0>	MVOyNlQ{PTZ4OR?=
LOXIMVI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG2Ok4zKM7:TR?=	M{WwPFczKGh?	MW\EUXNQ	NXS0NG1NT0l3ME2xJO69VQ>?	Mm\0NlI1OzV4Nkm=
M14	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\oOk4zKM7:TR?=	Mn3NO\|IhcA>?	MV3EUXNQ	NHn6OphIUTVyPUGuN{DPxE1?	MXSyNlQ{PTZ4OR?=
MALME-3M	M{XWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjmRW03NjJizszN	NG\4ZVA4OiCq	NU\UTJNyTE2VTx?=	M3PnfGdKPTB;MD6zNkDPxE1?	MmK5NlI1OzV4Nkm=
MCF10A	M3zRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP6Ok4zKM7:TR?=	NULReJFOPDhiaB?=	M17EdmROW09?	MVHHTVUxRTlwNjFOwG0>	Mn\0NlI1OzV4Nkm=
MDA-MB-435	NVv1RmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYi2MlIh\|ryP	M2e0WlczKGh?	Mln4SG1UVw>?	NUO1dJl7T0l3ME2wMlUh\|ryP	NYX6[FFWOjJ2M{W2Olk>
MDA-MB-468	M{G2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWW2MlIh\|ryP	NHOy[Y44OiCq	MX;EUXNQ	MorlS2k2OD1yLk[zJO69VQ>?	NUTFNlBYOjJ2M{W2Olk>
MOLT4	M{jFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fhR\|YvOiEQvF2=	NXzMcnljPzJiaB?=	Mn;ySG1UVw>?	MXfHTVUxRTBwNDFOwG0>	Mny2NlI1OzV4Nkm=
NCI-ADR-RES	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDP[JJ6Pi5{IN88US=>	M36xNlczKGh?	M4DucWROW09?	MljlS2k2OD1yLkG2JO69VQ>?	NVnOdVVTOjJ2M{W2Olk>
NCI-H23	NUTEWGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC3Ok4zKM7:TR?=	MkTEO\|IhcA>?	Mlf3SG1UVw>?	MXLHTVUxRTFizszN	NX;0dmRQOjJ2M{W2Olk>
NCI-H322M	NVHsdow3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;ydlYvOiEQvF2=	MUW3NkBp	NHj6dFFFVVOR	NHLTR4dIUTVyPUCuO\|kh\|ryP	MYeyNlQ{PTZ4OR?=
NCI-H460	M1y5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXycY43NjJizszN	M173[FczKGh?	MXjEUXNQ	NVLDXVRPT0l3ME2wMlc6KM7:TR?=	MkDtNlI1OzV4Nkm=
NCI-H522	NEjWVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2X1c\|YvOiEQvF2=	M33BZVczKGh?	NGTEWIRFVVOR	M{PaNWdKPTB;MD61JO69VQ>?	NWDaUWZPOjJ2M{W2Olk>
OVCAR3	NUPIeldWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnNOk4zKM7:TR?=	NH\KU5g4OiCq	NGXTU2ZFVVOR	NUXvO2NvT0l3ME2xMlMh\|ryP	M{m2SlIzPDN3Nk[5
OVCAR4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHBWYdIPi5{IN88US=>	M2TXe\|czKGh?	M1K0c2ROW09?	M2ntPGdKPTB;NDFOwG0>	NUXjTWlDOjJ2M{W2Olk>
OVCAR5	NH\UfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO1fW9QPi5{IN88US=>	NUjOTWhZPzJiaB?=	M3;ZPGROW09?	NGTpTXZIUTVyPUCuO\|kh\|ryP	NE\JSXYzOjR\|NU[2PS=>
OVCAR8	NUHKd5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;LNIk3NjJizszN	MmXPO\|IhcA>?	M36wOGROW09?	Ml3LS2k2OD1yLkWg{txO	M3X3b\|IzPDN3Nk[5
RXF393	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MleyOk4zKM7:TR?=	MVi3NkBp	M3fsUWROW09?	MXLHTVUxRTFwMzFOwG0>	M330c\|IzPDN3Nk[5
SF268	NFPqO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NECxUmk3NjJizszN	M3fFZ\|czKGh?	NVrxUYJPTE2VTx?=	NXX6elZVT0l3ME2xMlYh\|ryP	NXrxW28zOjJ2M{W2Olk>
SF295	NYP0W\|JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWwb5pGPi5{IN88US=>	M3PidlczKGh?	NEnpWZVFVVOR	M3rNTWdKPTB;MT62JO69VQ>?	MYqyNlQ{PTZ4OR?=
SF539	M2XaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUK2MlIh\|ryP	MUW3NkBp	NITTZ\|JFVVOR	NGPXUJBIUTVyPUKg{txO	NF30OXEzOjR\|NU[2PS=>
SK-MEL-2	NV\zR4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWK0OmFNPi5{IN88US=>	MVq3NkBp	NFHkUItFVVOR	Mk\rS2k2OD1zLkOg{txO	NE[zSFAzOjR\|NU[2PS=>
SK-MEL-28	M1r2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TuXVYvOiEQvF2=	NW\GeG9DPzJiaB?=	NGrIeGFFVVOR	MXjHTVUxRTFizszN	NIXVNVgzOjR\|NU[2PS=>
SK-MEL-5	NIK4[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDXOk4zKM7:TR?=	M3fBR\|czKGh?	M3LoWGROW09?	Moi4S2k2OD1yLk[zJO69VQ>?	NYfwNFFzOjJ2M{W2Olk>
SKOV3	NXGyV4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HNZlYvOiEQvF2=	M{HBNVczKGh?	MYLEUXNQ	M2\OR2dKPTB;MTFOwG0>	M2X3elIzPDN3Nk[5
SN12C	NHzqTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUK2MlIh\|ryP	MUS3NkBp	MnTtSG1UVw>?	M3u2cmdKPTB;MjFOwG0>	MUGyNlQ{PTZ4OR?=
SNB19	NFPFOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTKOk4zKM7:TR?=	MXW3NkBp	NULxe2F2TE2VTx?=	MWfHTVUxRTBwNkOg{txO	MlewNlI1OzV4Nkm=
SNB75	NGnRWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYS2MlIh\|ryP	MVi3NkBp	M32yN2ROW09?	NHjCZ3pIUTVyPUCuO\|kh\|ryP	NHru[pYzOjR\|NU[2PS=>
SR	NGL4NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\sOk4zKM7:TR?=	Moe2O\|IhcA>?	NYLySVZWTE2VTx?=	NGe5UYhIUTVyPUCuOEDPxE1?	Mm\RNlI1OzV4Nkm=
T47D	M13OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m4ZlYvOiEQvF2=	NXnCbIxTPzJiaB?=	M{\ZSGROW09?	NIHMXFhIUTVyPUCuOUDPxE1?	MkLuNlI1OzV4Nkm=
TK10	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP5cFg3NjJizszN	M2PSbVczKGh?	MnGySG1UVw>?	NYDI[Hh{T0l3ME2wMlY{KM7:TR?=	NG\Gc\|MzOjR\|NU[2PS=>
UACC257	M4\RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[2MlIh\|ryP	MkXRO\|IhcA>?	NIn4THVFVVOR	MoDLS2k2OD1yLkWg{txO	NEjET\|UzOjR\|NU[2PS=>
UACC62	NYjVUXNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVi2MlIh\|ryP	M4WxdFczKGh?	M2TvW2ROW09?	MUnHTVUxRTBwNDFOwG0>	MU[yNlQ{PTZ4OR?=
UO31	NFvCbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnsOk4zKM7:TR?=	NFzB[pk4OiCq	NXfXPYJNTE2VTx?=	MUTHTVUxRTBwNTFOwG0>	NU\K[4g5OjJ2M{W2Olk>
Hep3B	M13yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV7BZVBtPDhiaB?=	MlfhSG1UVw>?	NFT2XJNIUTVyPUCuOlkh\|ryP	MYmyNlQ{QTh4Mx?=
BE(2)-C	M1;Mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLoN3VCPzJiaB?=	NVTNfIFWTE2VTx?=	M13lb2lEPzB;MjFOwG0>	M1f2fFIzQTN{M{G2
Bel7402	NE[0VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUW3NkBp	M3nqO2ROW09?	NWTDbo41T0l7ME2xO{DPxE1?	MonVNlMxPjF\|N{[=
Bel7404	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PBSFczKGh?	NILxbpVFVVOR	M4O0PGdKQTB;MUig{txO	NVjtW5pjOjNyNkGzO\|Y>
BGC823	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGrSPGw4OiCq	Mn\5SG1UVw>?	MUXHTVkxRTdwNTFOwG0>	M{jITFI{ODZzM{e2
MGC803	M1nRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUW3NkBp	MWTEUXNQ	NU\5VllnT0l7ME2xNE45KM7:TR?=	MWeyN\|A3OTN5Nh?=
SGC7901	NVf3[VZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXq3NkBp	NVPj[Yx2TE2VTx?=	NEm2SINIUTlyPUmuOEDPxE1?	NY[4UlM1OjNyNkGzO\|Y>
SKHEP1	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWDSbGVyPzJiaB?=	NET0XopFVVOR	Ml20S2k6OD1zNzFOwG0>	M3;pUFI{ODZzM{e2
SMMC7721	NYXDfIRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MW[3NkBp	NE[0fZpFVVOR	M3TIemdKQTB;MkCg{txO	M3OyO\|I{ODZzM{e2
NUGC3	NGnE[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\LNVAh\|ryP			NE\TZWtIUT1{Lkm0JO69VQ>?	Mn7mNlMyPjN\|M{K=
A2780 CisR	M{nN[GtqdmG\|ZTDBd5NigQ>?		NGfzeHgyQCCq		NWnBVnNuUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	NYXjR5pHOjN{NUK2NFM>
CAL27 sens	MnS3T4lv[XOnIFHzd4F6		M{jpfFE5KGh?		MX7Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{[g{txO	NV\RfnFQOjN{NUK2NFM>
CAL27 CisR	M{L4U2tqdmG\|ZTDBd5NigQ>?		MWixPEBp		MljUTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	M1\qc\|I{OjV{NkCz
KYSE-510 CisR	NVHFbVJHU2mwYYPlJGF{e2G7		M2XGcVE5KGh?		NGjESHRKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOVkh\|ryP	M4jLUVI{OjV{NkCz
KYSE-510 sens	M3ThWWtqdmG\|ZTDBd5NigQ>?		Mo\FNVghcA>?		MXnJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNzFOwG0>	NWXLWolYOjN{NUK2NFM>
MDA-MB-231 sens	NYPtTZU3U2mwYYPlJGF{e2G7		MWmxPEBp		NGjRfYJKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	NFnIfYIzOzJ3Mk[wNy=>
MDA-MB-231 CisR	NEDxT4ZMcW6jc3WgRZN{[Xl?		NYHmSHgyOThiaB?=		MoPjTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	M17mU\|I{OjV{NkCz
ES2	M{fJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PYdlQ5KGh?	NYjsOWduTE2VTx?=	MmewTWM2OD1zMj63JO69VQ>?	MoLoNlM1QTN2NEm=
MDA-MB-231	NVK1cXBRU2mwYYPlJGF{e2G7	MonWNVAh\|ryP	MU[zNEBucW5?	NG[0VIpFVVOR	NVntTXNJUW6qaXLpeIlwdiCxZjDISGFEOmF?	MlTFNlM1QTN2NEm=
MDA-MB-231	M{DkbWtqdmG\|ZTDBd5NigQ>?	MmPvNUDPxE1?	MYWyOEBp	M{Lzc2ROW09?	M2[weGlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	M1fueVI{PDl\|NES5
HS68	NUjXOHVWS3m2b4TvfIlkKEG\|c3H5	MlPuNVAh\|ryP	MkTBO\|IhcA>?	NW\5T5N1TE2VTx?=	MV7JR\|UxRTRwNjFOwG0>	NHK1SVIzOzV5MEW0Ni=>
MEF	M13M[WN6fG:2b4jpZ{BCe3OjeR?=	NGfv[ZUyOCEQvF2=	M2L5RlczKGh?	NXfpTFVMTE2VTx?=	NETWd21KSzVyPUSuOEDPxE1?	NXv3c2JrOjN3N{C1OFI>
BGC823	NFLydVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEDpeFRFVVOR	MWLHTVUxRTNwMEmg{txO	NEWyeJozOzZyMUewOi=>
High5	M{PuZWtqdmG\|ZTDBd5NigQ>?		NUjH[Gk2OjRiaB?=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JJdqfGhiSVO1NEBw\iByLkC5JO69VQ>?	NXH4O41YOjN4MEK1NlM>
High5	NELmZplMcW6jc3WgRZN{[Xl?		MYqyOEBp		NIHZU3lKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlEzKM7:TR?=	MnHFNlM3ODJ3MkO=
High5	NFHVb2xMcW6jc3WgRZN{[Xl?		M3;4flI1KGh?		NFvxenFKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?=	Mn7ENlM3ODJ3MkO=
A549	M3TUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2XhUmROW09?	NH74[HVKSzVyPUGuNFc6KM7:TR?=	MUCyN\|Y1PDJzMB?=
HCT116	NUGweYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHi4TXBFVVOR	MV7JR\|UxRTBwN{W3JO69VQ>?	MXqyN\|Y1PDJzMB?=
K562	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIjHOIdFVVOR	MmP0TWM2OD1yLk[0OUDPxE1?	MUeyN\|Y1PDJzMB?=
GBC-SD	NIPUc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf6SoxxPSEQvF2=	Mmi0O\|IhcA>?	NXrYdHQ2TE2VTx?=	MX7JR\|UxRTF2Lkig{txO	Mnq3NlM4ODd{NkC=
HGC27	NV32dWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXyOUDPxE1?	M4DEblczKGh?	NGnBV3hFVVOR	NEK2e\|RKSzVyPUWuOEDPxE1?	NIXiclQzOzdyN{K2NC=>
HL60	MmPMT4lv[XOnIFHzd4F6	M3fUN\|Uh\|ryP	M3qzPVI1KGh?	NFv3c2tFVVOR	MV7Jcohq[mm2aX;uJI9nKEiGQVO=	MVqyN\|cxPzJ4MB?=
Vero	M371O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17KbFczKGh?	Moq2SG1UVw>?	MUHJR\|UxRTBwOTFOwG0>	NUP1XoJiOjN5OE[0OVI>
NCI60	MYnDfZRwfG:6aXOgRZN{[Xl?		MoHpOFghcA>?	NGnW[mRFVVOR	NF;mXYtIUT1yLkWzJO69VQ>?	NI[xXI4zPDBzNUOyOy=>
SW620	MlXsR5l1d3SxeHnjJGF{e2G7		M4qzVVQ5KGh?	NXPxcZFpTE2VTx?=	MWHHTV0xNjV2IN88US=>	MWCyOFAyPTN{Nx?=
U251	MkfiR5l1d3SxeHnjJGF{e2G7		MknkOFghcA>?	NF;PNYJFVVOR	NFXwRVlIUT1zLkWzJO69VQ>?	Mn7nNlQxOTV\|Mke=
KM12	M3jrT2N6fG:2b4jpZ{BCe3OjeR?=		M2HtV\|Q5KGh?	MlfOSG1UVw>?	MlGwS2k:OS56ODFOwG0>	NUe4[FJROjRyMUWzNlc>
Hs578T	MVzDfZRwfG:6aXOgRZN{[Xl?		NFTaZnA1QCCq	MWPEUXNQ	MYLHTV01Njh\|IN88US=>	NEf6cIwzPDBzNUOyOy=>
MDA-MB-231	NFvHbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13oV\|Q5KGh?		M4rDR2lEPTB;MD6xOkDPxE1?	M2TyUFI1ODl3MEG2
MCF7	NHjIbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX[0PEBp		Mm[zS2k:OC52NTFOwG0>	NHTlUHEzPDFzOUW1OS=>
MDA-MB-435	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPIOIw1QCCq		NXm0dnFRT0l;MD64PEDPxE1?	NGrXb\|czPDFzOUW1OS=>
AsPC1	NFHUVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUezNEDPxE1?	NFrxSIs1QCCq	NX;JZpljTE2VTx?=	MoTLTWM2OD1\|Lk[2JO69VQ>?	Mo\aNlQyQDV\|N{i=
Jurkat E6.1	NUTxW3NjU2mwYYPlJGF{e2G7		MW[yJIg>	NHq2UodFVVOR	MljZTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	NFjpenIzPDJ4MUi2Ni=>
KG1	NGjiO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrJOFghcA>?		NFry[GNKSzVyPUGuNVUh\|ryP	M1\MRVI1PTJ3MECz
HEL	M1O3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUC0PEBp	M33hUWROW09?	NVTtZpFEUUN3ME2wMlQ6KM7:TR?=	NEfreGMzPDZ7NEC1OS=>
HSC3	M3no[GN6fG:2b4jpZ{BCe3OjeR?=		M4n1cFEzKGh?	MlqxSG1UVw>?	NWCxV\|VGUUN3ME2wMlcyKM7:TR?=	MUKyOFc3PjV4MB?=
HT-29	Mm\FR5l1d3SxeHnjJGF{e2G7		NH3DSpEyOiCq	M4PRdmROW09?	M{TSc2lEPTB;MD63NkDPxE1?	NUTtWFZiOjR5Nk[1OlA>
KB	NUXHcHFyS3m2b4TvfIlkKEG\|c3H5		M{fsd\|EzKGh?	NIew[nBFVVOR	NFi1[HZKSzVyPUCuO\|Uh\|ryP	NEHlXFAzPDd4NkW2NC=>
H460	NYDEOHh[S3m2b4TvfIlkKEG\|c3H5		NEXIOXoyOiCq	MmrMSG1UVw>?	NGr5RmdKSzVyPUCuPFIh\|ryP	NHjybWQzPDd4NkW2NC=>
MONE1	MoLxR5l1d3SxeHnjJGF{e2G7		NGPDUXQyOiCq	MlGzSG1UVw>?	MWDJR\|UxRTFwMUig{txO	NHfUcIMzPDd4NkW2NC=>
MKN45	NVfVb\|ZoS3m2b4TvfIlkKEG\|c3H5		Mni1NVIhcA>?	NIP3OohFVVOR	MmHCTWM2OD1zLkK1JO69VQ>?	Mn7jNlQ4PjZ3NkC=
TSGH	NGr5VWtEgXSxdH;4bYMhSXO\|YYm=		MmLqNVIhcA>?	M1zoOWROW09?	NETsNI9KSzVyPUKuNFkh\|ryP	M{f0NFI1PzZ4NU[w
HL60	M{PE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{K3NFczKGh?	MWTEUXNQ	NFnFWGNIUTVyPUCuPVMh\|ryP	M1PmSVI1QTByNUCw
HEK293	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVO3NkBp	MV;EUXNQ	NEXRSo1IUTVyPUGzJO69VQ>?	MnrmNlQ6ODB3MEC=
Jurkat	M{PsbGN6fG:2b4jpZ{BCe3OjeR?=	MYqxNFAh\|ryP	MXO3NkBp		NYe0V2oyT0l3ME2wMlkh\|ryP	MnvmNlQ6ODB5NEO=
GM15850	NHvtSWtMcW6jc3WgRZN{[Xl?	M3jTVVIvPSEQvF2=	M4LxXVk3KGh?	M3GzSmROW09?	M3\vcYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UAyPCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NIH2cXAyPjl{MUO2Oy=>
GM15850	M{jpbWtqdmG\|ZTDBd5NigQ>?	MV2yMlUh\|ryP	MoD2PVYhcA>?	M2K3NGROW09?	MWHkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	MXuxOlkzOTN4Nx?=
GM15850	MoHhT4lv[XOnIFHzd4F6	NWfxSZhNOi53IN88US=>	MoG3PVYhcA>?	NGX3UJRFVVOR	MW\kc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MXixOlkzOTN4Nx?=
GM15850	MoHXT4lv[XOnIFHzd4F6	MXuyMlUh\|ryP	NYPQdIJNQTZiaB?=	M1LifGROW09?	M{GxZYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UA6KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NXPVTlVMOTZ7MkGzOlc>
GM15850	NX2xW\|JXU2mwYYPlJGF{e2G7	MUeyMlUh\|ryP	M2fkZ\|k3KGh?	M2nBWWROW09?	NH;kUGhld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhQCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	Mn;WNVY6OjF\|Nke=
GM15850	NGO2WWFMcW6jc3WgRZN{[Xl?	MnjCNk42KM7:TR?=	NV;QT3RJQTZiaB?=	NXT5cZN3TE2VTx?=	MmD6[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MkPENVY6OjF\|Nke=
GM15850	MWjGeY5kfGmxbjDBd5NigQ>?	MYG1JO69VQ>?	MUixNkBp	NXnoVnFvTE2VTx?=	NGTKOI9p[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	NEPPdnkyPjl{MUO2Oy=>
U937	MVHLbY5ie2ViQYPzZZk>	MY[1JO69VQ>?	M4XrdFI1KGh?	Moe0SG1UVw>?	MWjoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	NFGxbIUyPzR2N{e1NC=>
U937	MUHLbY5ie2ViQYPzZZk>	NELnNowyKM7:TR?=	MVmyOEBp	NXL0VVRuTE2VTx?=	Ml;KbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	MoLVNVc1PDd5NUC=
PANC1	MmCxSpVv[3Srb36gRZN{[Xl?	NFS2enYyKM7:TR?=	NHLJ[\|MzPCCq		NYjpVmdC\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NHjJSGUyPzV6OEe0OC=>
PANC1	M320[2Z2dmO2aX;uJGF{e2G7	MYGxJO69VQ>?	NXH2d5pxPDhiIHi=		MVHkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	MWexO\|U5QDd2NB?=
Caco-2	Ml;4SpVv[3Srb36gRZN{[Xl?	MWe1JO69VQ>?	NEHlPW0zPCCq	NVPx[45FTE2VTx?=	MUDkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	NFu2TowzODF2M{i0NC=>
SCC4	M3rPZWZ2dmO2aX;uJGF{e2G7	NHLMbGYyKM7:TR?=	M1W4W\|ExKG2rbh?=	M16wN2ROW09?	NV\peFVGcGG\|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	M2rXe\|IxPDV{MkK1
A549	NEnoNWRHfW6ldHnvckBCe3OjeR?=	NUTpWHZ3PSEQvF2=	NI\QNmk{KGh?	Ml3ySG1UVw>?	NX;hTFVz\G:nczDuc5QhcW6mdXPlJIF2fG:yaHHnfUBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR\|NKUQ>?	NFzVTIEzODh3NUKwPC=>
HCT116	MnvUT4lv[XOnIFHzd4F6	NVnFXJY4OC5\|IN88US=>	MUSzNEBp	MU\EUXNQ	NH32OY5ld2W\|IH7veEBqdmirYnn0JGhFSUNzIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqaYP0c45mKEh\|S{mgZYNmfHmuYYTpc44>	NIT6SYkzOTB6ME[0Oy=>
HepG2	NYP2NZhwTnWwY4Tpc44hSXO\|YYm=	Mn7GNVAh\|ryP	M130fVI1KGh?	MlzSSG1UVw>?	M{XSS4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO=	M{HHWVIyPTR6NUiy
GM11272	NGHOeJdHfW6ldHnvckBCe3OjeR?=	Mn3iNE4yKM7:TR?=	M3zFW\|czKGh?	MXfEUXNQ	M3zFe4Rw\XNibn;0JJJm[WO2aY\heIUhVWWFcEKgcZV1[W62IHX4dJJme3Orb36=	NGPPfXczOTh2MEexOi=>
MDA-MB-231	M4rJc2tqdmG\|ZTDBd5NigQ>?	NEf2cWMyOCEQvF2=	NYfPSpg2PSCvaX6=	M4[3RWROW09?	MUnkc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>?	MX6yN\|Q6OzR2OR?=
MDA-MB-231	M{i5PWtqdmG\|ZTDBd5NigQ>?	MWGxJO69VQ>?	NYHnXnVFOjRiaB?=	NYHiXmJGTE2VTx?=	M4jKVoRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	M1vVWlI{PDl\|NES5
K562	MYHLbY5ie2ViQYPzZZk>				NFnIOGdld2W\|IH7veEBqdmirYnn0JGhFSUN?	NVfFfGVpOjN3OUGxNVE>
Jurkat	NU\EbpZyS3m2b4TvfIlkKEG\|c3H5	NEW1SWQzOCEQvF2=	NIXjXXQ4OiCq	M{DvZ2ROW09?	NUTmR41Ndm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9v	NF;BTFMzPDNyNEO0PC=>
HCT116	NEjmUpZCeG:ydH;zbZMhSXO\|YYm=	NGPUeI0{KM7:TR?=	NUnFbWhbOjRiaB?=	NHTRT4FFVVOR	MXvkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHB3MzDwdo91\WmwIHzleoVt	M4LJT\|I1PzZ4NU[w
KASUMI-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTl7LkG3JI5O	MlHUV2FPT0WU
KARPAS-45	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHexTW1KSzVyPUG3N{45QSCwTR?=	M1LS[HNCVkeHUh?=
BHT-101	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnaSJBkUUN3ME2yOFQvOThibl2=	NGjDVIVUSU6JRWK=
H9	NWDNZmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWCxcFBOUUN3ME2yOVUvODRibl2=	M4jkZnNCVkeHUh?=
PA-1	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPKb2pxUUN3ME2yPFYvOjZibl2=	NHrueHNUSU6JRWK=
NEC8	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;qU49nUUN3ME2yPFkvOzhibl2=	MXfTRW5ITVJ?
MHH-PREB-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjiWVhKSzVyPUK5OE42OyCwTR?=	NG\0U4hUSU6JRWK=
NB7	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWezeYxnUUN3ME2zOFUvPzRibl2=	NX;4T4wyW0GQR1XS
A3-KAW	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTRyMD61PUBvVQ>?	MYPTRW5ITVJ?
NB69	M{HqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrqSpN6UUN3ME20NVEvPzFibl2=	NWDHXIV{W0GQR1XS
EoL-1-cell	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTR3NEK1JI5O	MVXTRW5ITVJ?
CHP-212	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\pPZRKSzVyPUS1O{42OyCwTR?=	M136WXNCVkeHUh?=
C2BBe1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\BTWM2OD12N{KuNVkhdk1?	MmLsV2FPT0WU
697	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fyd2lEPTB;NEezMlQyKG6P	NIfo[WdUSU6JRWK=
BCPAP	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nLR2lEPTB;NUCxMlQzKG6P	M3X5T3NCVkeHUh?=
L-363	NYjn[ZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH62T2ZKSzVyPUWwN{4yKG6P	NFXwU\|VUSU6JRWK=
ES8	NVL3[2ttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33XN2lEPTB;NUKzMlU{KG6P	MnPEV2FPT0WU
BE-13	NIfTSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jQN2lEPTB;NUK2Mlk3KG6P	NVK0OW9DW0GQR1XS
CTB-1	NHXCPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7uPFdKSzVyPUWzO{46OiCwTR?=	MmXQV2FPT0WU
HD-MY-Z	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[wSodkUUN3ME21N\|gvOTNibl2=	MnHGV2FPT0WU
NKM-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL5SHVXUUN3ME21OFQvOjdibl2=	MWLTRW5ITVJ?
NCI-H720	NIXRRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;4eGlEPTB;NU[wMlE5KG6P	NIPNTmFUSU6JRWK=
KY821	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjCTWM2OD13NkOuNlUhdk1?	Mn72V2FPT0WU
OVCAR-5	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTV5Nj6xNUBvVQ>?	Mo\tV2FPT0WU
CTV-1	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTV6MT61OkBvVQ>?	Mn;YV2FPT0WU
P12-ICHIKAWA	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTV7Nj61NUBvVQ>?	M33Fb3NCVkeHUh?=
DB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\CdmlEPTB;NUm4MlU4KG6P	NIThZmtUSU6JRWK=
CHL-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzYVZBKUUN3ME22OFIvODhibl2=	MlzkV2FPT0WU
A4-Fuk	NY\CWI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHv1[VBKSzVyPU[0OE46OSCwTR?=	MV;TRW5ITVJ?
MV-4-11	M1Wzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\3N2tKSzVyPU[1PU4yKG6P	NV3Hbo1WW0GQR1XS
RPMI-8226	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfMbnRmUUN3ME22O\|gvOThibl2=	NVXENIpKW0GQR1XS
NB14	NGXDN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjUeZVKSzVyPU[5Ok46PSCwTR?=	MXfTRW5ITVJ?
DOHH-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPhTWM2OD15ME[uOlghdk1?	M1rtdnNCVkeHUh?=
D-423MG	M33LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFixVYZKSzVyPUewOk45QSCwTR?=	NEmydmJUSU6JRWK=
D-283MED	NILzbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTJTWM2OD15MUSuNVQhdk1?	NWH3XZZ6W0GQR1XS
ES1	NVrFe2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTd{ND60JI5O	M3n0XnNCVkeHUh?=
GOTO	Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jVOGlEPTB;N{K5MlEzKG6P	Ml\lV2FPT0WU
NCI-H209	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTd{OT65JI5O	MoPYV2FPT0WU
MOLT-13	NUfXcolZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzPNIpKSzVyPUezPE46QCCwTR?=	NWriNJBWW0GQR1XS
ATN-1	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfzRXhKSzVyPUe0NE4zQCCwTR?=	Mmq1V2FPT0WU
DU-4475	Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jvPWlEPTB;N{WxMlkyKG6P	MlnvV2FPT0WU
NB10	NHHNcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnjTWM2OD15NUGuPVIhdk1?	MVnTRW5ITVJ?
KG-1	NWPK[I5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXhTWM2OD15N{WuOFUhdk1?	NEC0PZJUSU6JRWK=
MOLT-4	M1XBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHqeopKSzVyPUe4O{41PiCwTR?=	NF:1U\|ZUSU6JRWK=
TE-1	NXG0N2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILLbnlKSzVyPUe5NU4yKG6P	NHP3NFZUSU6JRWK=
SBC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLmTWM2OD15OUOuPFQhdk1?	M3HJUnNCVkeHUh?=
HEL	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfnTFFSUUN3ME24NFYvODhibl2=	MYjTRW5ITVJ?
SK-MEL-2	NGG5bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DDT2lEPTB;OEC5MlQ1KG6P	NUPmW4lKW0GQR1XS
KU812	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjP[GZKSzVyPUixN{4yKG6P	M2G2e3NCVkeHUh?=
RPMI-8866	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHlVmpKSzVyPUixN{43PyCwTR?=	M2LWXnNCVkeHUh?=
ALL-PO	NW\1fnpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTvTWM2OD16MUSuOlYhdk1?	NUPSZWJ{W0GQR1XS
LU-139	NWTrPFB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HqbWlEPTB;OEKyMlg3KG6P	MmjkV2FPT0WU
RS4-11	NHPFR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLhSXJKSzVyPUizNk41PSCwTR?=	NGDXemtUSU6JRWK=
EW-18	NWLlfFNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrGTWM2OD16M{KuPVYhdk1?	MkD4V2FPT0WU
P30-OHK	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\XTGlEPTB;OEO1Mlchdk1?	NYTEdFJTW0GQR1XS
D-566MG	NXrKUo05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTh\|OD62NkBvVQ>?	NX\BXYhIW0GQR1XS
HSC-4	NGnrWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\ZTWM2OD16NE[uOVEhdk1?	M2qxfHNCVkeHUh?=
QIMR-WIL	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVuycFYzUUN3ME24OlIvODNibl2=	NGT6NFVUSU6JRWK=
SW954	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTKTWM2OD16NkOuNVYhdk1?	M1vYUHNCVkeHUh?=
HGC-27	NHHKcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn4TWM2OD16N{KuN\|Qhdk1?	NEi3cW9USU6JRWK=
HH	NFr6dYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\0bZJKSzVyPUi5OE4yOiCwTR?=	NUeyOWZuW0GQR1XS
KE-37	M4PKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fRVmlEPTB;OEm0MlYzKG6P	M{jWPXNCVkeHUh?=
SK-N-DZ	NWDtSmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILGVodKSzVyPUmwNE41OyCwTR?=	NHXRdWJUSU6JRWK=
J-RT3-T3-5	M2XuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnsWGFKSzVyPUmxNE41QSCwTR?=	NXL3Wpg3W0GQR1XS
A427	NGfsT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW1XG1KSzVyPUmyNE45PCCwTR?=	MnLxV2FPT0WU
ECC10	NYPTRpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHsTXFKSzVyPUm0OU45PyCwTR?=	NXLZRmNJW0GQR1XS
EW-1	NWPUbI51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\W[o1VUUN3ME25OFcvOjZibl2=	NVv2OVltW0GQR1XS
MIA-PaCa-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLiTWM2OD17NEmuNVIhdk1?	MnXxV2FPT0WU
HCC2218	NH;Sb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTl3OD60PEBvVQ>?	M{\PdnNCVkeHUh?=
HAL-01	NGrzT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLzN5BKSzVyPUm2PE4xPCCwTR?=	MVfTRW5ITVJ?
RD	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4H4e2lEPTB;OUe0MlQ2KG6P	MmTEV2FPT0WU
SK-N-AS	M1;xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTl6OD6xJI5O	NFTG[VJUSU6JRWK=
ML-2	NGO2VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PXV2lEPTB;MT6wNFQxPyEQvF2=	NGL5VFhUSU6JRWK=
MEL-HO	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfuW2l{UUN3ME2xMlAxPTh{IN88US=>	MnnIV2FPT0WU
MS-1	NX3BcnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\PPYhUUUN3ME2xMlAxPjF5IN88US=>	NXzxXGR[W0GQR1XS
NCI-SNU-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\YbVR5UUN3ME2xMlAzOzNzIN88US=>	MV;TRW5ITVJ?
8505C	NI\2NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jINmlEPTB;MT6wNlM{OSEQvF2=	MlPOV2FPT0WU
MN-60	NVnKSFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3JTWM2OD1zLkCyOlgh\|ryP	M1TpW3NCVkeHUh?=
SAS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzMcYJXUUN3ME2xMlA1ODhzIN88US=>	Mn7BV2FPT0WU
EFM-19	NHLZdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HvVGlEPTB;MT6wOFg4QSEQvF2=	NEW3PJNUSU6JRWK=
Ca9-22	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPiTWM2OD1zLkC1NVA4KM7:TR?=	Mn\lV2FPT0WU
NBsusSR	NYrKTZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX:yO21lUUN3ME2xMlA2OTZ4IN88US=>	M3\Hc3NCVkeHUh?=
NB13	NHz3WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zhbWlEPTB;MT6wOVUxOSEQvF2=	M{HUOXNCVkeHUh?=
SF295	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFwME[2NlQh\|ryP	NGHzeJFUSU6JRWK=
U-2-OS	M3n5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq0V29KSzVyPUGuNFc6OTFizszN	MmL5V2FPT0WU
NCI-H526	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HweGlEPTB;MT6wPFI6OSEQvF2=	NVfne3QxW0GQR1XS
KMOE-2	M2n3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHv6SJJKSzVyPUGuNFk1OjJizszN	M{C2cnNCVkeHUh?=
RCM-1	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPZbIs{UUN3ME2xMlEzOTB{IN88US=>	M4mwXXNCVkeHUh?=
MC116	NELu[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELnNZlKSzVyPUGuNVM3OjFizszN	NHzGOlJUSU6JRWK=
NCI-H1092	NU\6XZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljFTWM2OD1zLkG1OFA3KM7:TR?=	NYnJcXNjW0GQR1XS
EW-3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7GS5JXUUN3ME2xMlE4OjF{IN88US=>	NX;UOYpMW0GQR1XS
HCT-116	M1GwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnCc3VKSzVyPUGuNVc4PSEQvF2=	MojzV2FPT0WU
MC-IXC	MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTFwMUe4PFEh\|ryP	Ml[yV2FPT0WU
LB1047-RCC	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoCxTWM2OD1zLkG4N\|EzKM7:TR?=	MmfMV2FPT0WU
VM-CUB-1	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;p[3Z7UUN3ME2xMlE6OTB6IN88US=>	M3jOcHNCVkeHUh?=
NB5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrzRmdVUUN3ME2xMlE6QDV4IN88US=>	NEfQUVFUSU6JRWK=
SKG-IIIa	NWjDeWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\lTWM2OD1zLkKzOFY1KM7:TR?=	M{ft[XNCVkeHUh?=
HO-1-N-1	Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnzTWM2OD1zLkKzPFM2KM7:TR?=	M3rHS3NCVkeHUh?=
EFO-27	NETleoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvFVYZ1UUN3ME2xMlI2ODR\|IN88US=>	MX7TRW5ITVJ?
MHH-NB-11	M{\jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVq0WXVEUUN3ME2xMlI5OzJ7IN88US=>	NFWzbWFUSU6JRWK=
SW620	NGntRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlqxTWM2OD1zLkK5NFE5KM7:TR?=	M4DLVnNCVkeHUh?=
MOLT-16	M{j3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnKN2RPUUN3ME2xMlI6Pzl5IN88US=>	M2G4XnNCVkeHUh?=
NTERA-S-cl-D1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nzdmlEPTB;MT6zNVc3OSEQvF2=	MVHTRW5ITVJ?
VA-ES-BJ	M{\RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1O3NmlEPTB;MT6zNlQ4PyEQvF2=	MlPVV2FPT0WU
HCC1419	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjGTWM2OD1zLkO0NFI4KM7:TR?=	NYHyNYtMW0GQR1XS
NCI-H69	NWXYdWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHCcpRuUUN3ME2xMlM1OTF{IN88US=>	M{LkSXNCVkeHUh?=
DEL	M1m4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXLTWM2OD1zLkO1NVYzKM7:TR?=	M1HE[HNCVkeHUh?=
LXF-289	NInxR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfHb4FQUUN3ME2xMlM2OjRizszN	MUjTRW5ITVJ?
EW-11	NGnQVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTxTWM2OD1zLkO2NFI3KM7:TR?=	NIHpPIdUSU6JRWK=
KP-4	NF23OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjsdlVKSzVyPUGuN\|cxQDVizszN	M3vk[XNCVkeHUh?=
NOS-1	NVW4WHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLpTWM2OD1zLkSxNVk1KM7:TR?=	NIHqSGxUSU6JRWK=
SK-NEP-1	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHt[GdEUUN3ME2xMlQyPjl\|IN88US=>	NUizbIJmW0GQR1XS
LAMA-84	NFjIWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjUXFFKSzVyPUGuOFM6PDVizszN	NHLXdJhUSU6JRWK=
ES5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7KZVVWUUN3ME2xMlQ1OyEQvF2=	NGLnWYVUSU6JRWK=
HuO9	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFwNEWzOlIh\|ryP	MYjTRW5ITVJ?
COLO-684	M1zxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PYVGlEPTB;MT60OlEyQCEQvF2=	NWm3Z5hEW0GQR1XS
EW-24	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXvOHdKSzVyPUGuOFY2OzFizszN	NF\Cb2dUSU6JRWK=
BV-173	M4fCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFriU5hKSzVyPUGuOFczQTFizszN	NWq4b3JVW0GQR1XS
NCI-H1770	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rzTmlEPTB;MT60PFU{PiEQvF2=	M3vLcXNCVkeHUh?=
HuP-T4	NVfRTnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPmTWM2OD1zLkS5N{DPxE1?	NUO1cYdLW0GQR1XS
TYK-nu	M4fDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Lk[GlEPTB;MT60PVg2OSEQvF2=	NFO1SZhUSU6JRWK=
YH-13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vOXGlEPTB;MT60PVg6PCEQvF2=	NVfIVG9wW0GQR1XS
H4	NVXOeJk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHodWdKSzVyPUGuOVA6OTJizszN	MoD5V2FPT0WU
OVCAR-8	M13SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFwNUS0O\|ch\|ryP	NV;USGIzW0GQR1XS
NCI-H23	NF7yPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXVTWM2OD1zLkW0OlQ2KM7:TR?=	NITwbVJUSU6JRWK=
ES7	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XuRWlEPTB;MT61OFc4OyEQvF2=	M2PXZnNCVkeHUh?=
COR-L88	NGDxNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrpfoRbUUN3ME2xMlU3PDJ2IN88US=>	NGixSmlUSU6JRWK=
TI-73	MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGX4UHlKSzVyPUGuOVkxPiEQvF2=	NV7wclh7W0GQR1XS
RT-112	NGi3eJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\EUGlEPTB;MT61PVI5PCEQvF2=	NGi1PFlUSU6JRWK=
HuO-3N1	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[xRYtHUUN3ME2xMlU6Ozh3IN88US=>	M3zaVXNCVkeHUh?=
HC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DBTGlEPTB;MT61PVg3PiEQvF2=	MnH6V2FPT0WU
HT55	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTUflZKSzVyPUGuOlUyOzFizszN	NHLxOFZUSU6JRWK=
IA-LM	M2nFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnvWVJKSzVyPUGuOlkzPzhizszN	NGGwNJFUSU6JRWK=
EM-2	NUfVeG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{f3RmlEPTB;MT63NFAyPCEQvF2=	NXmxelA1W0GQR1XS
MHH-ES-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorHTWM2OD1zLkewOFM2KM7:TR?=	NVnVdlZ[W0GQR1XS
CAL-27	M3zqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFj0dmNKSzVyPUGuO\|A3OjFizszN	NGPqTlBUSU6JRWK=
COLO-800	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\GeGlEPTB;MT63NVE4QSEQvF2=	M3zFdnNCVkeHUh?=
HCE-T	M13QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWntS5NjUUN3ME2xMlcyPSEQvF2=	NX;iVllIW0GQR1XS
CAMA-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTVTWM2OD1zLkexPVcyKM7:TR?=	NUf6eWsxW0GQR1XS
LOXIMVI	NHrMc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTFwN{KxNUDPxE1?	MnSxV2FPT0WU
NH-12	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2O0XWlEPTB;MT63NlY6OSEQvF2=	NYH5[\|FqW0GQR1XS
TCCSUP	M1zrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnmzTWM2OD1zLkeyPFI6KM7:TR?=	NF\teI1USU6JRWK=
MDA-MB-361	NFfJRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwN{OxOVch\|ryP	M3joXHNCVkeHUh?=
EW-16	M2XHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYn0ZmhtUUN3ME2xMlc1OTB5IN88US=>	M1\meHNCVkeHUh?=
SNU-423	NFjKVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTCfWlKSzVyPUGuO\|U5OjdizszN	MoPCV2FPT0WU
Daoy	M2\LbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\xVGlEPTB;MT63OlMyQSEQvF2=	M3\ETnNCVkeHUh?=
ES4	NETDbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwN{i3OFEh\|ryP	MV7TRW5ITVJ?
PFSK-1	M33LdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r1Z2lEPTB;MT64NFM4KM7:TR?=	M{HGOXNCVkeHUh?=
ES3	NFLJN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfDTWM2OD1zLkiyOlgyKM7:TR?=	MoLYV2FPT0WU
ONS-76	MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEf2UGxKSzVyPUGuPFI5QTdizszN	NHK3WYhUSU6JRWK=
JVM-3	NEPj[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFwOEW0OVEh\|ryP	M3vZSHNCVkeHUh?=
OS-RC-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3u5TGlEPTB;MT64O\|E2OSEQvF2=	MXvTRW5ITVJ?
COLO-320-HSR	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXq3SphDUUN3ME2xMlg5OTl5IN88US=>	NYS0[Ih3W0GQR1XS
HN	NVTZZm02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X3TmlEPTB;MT64PFczPSEQvF2=	M33YXHNCVkeHUh?=
HT	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXs[FhKSzVyPUGuPFg6PDdizszN	M1;qZnNCVkeHUh?=
LoVo	NF7jPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXLTWM2OD1zLki5PFEh\|ryP	NFT3TYRUSU6JRWK=
CGTH-W-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPoTWM2OD1zLki5PVQ3KM7:TR?=	MVzTRW5ITVJ?
NB6	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwOUGyPVgh\|ryP	M2PKVnNCVkeHUh?=
EW-22	NGfPTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmj1TWM2OD1zLkmyPFg4KM7:TR?=	MULTRW5ITVJ?
ES6	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjpcZdKSzVyPUGuPVM3OzFizszN	M2nzTXNCVkeHUh?=
SCC-15	M4PkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\RZWlEPTB;MT65N\|gyQSEQvF2=	MnPQV2FPT0WU
HL-60	M{TB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWyNHlKSzVyPUGuPVM6ODJizszN	MoLOV2FPT0WU
human HOP-92	M1vaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjYTWM2OD1zLkm0NFY2KM7:TR?=	NIPweXdUSU6JRWK=
SW626	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j5NmlEPTB;MT65OFg6QSEQvF2=	NYriWmpNW0GQR1XS
HEC-1	M373[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXZTWM2OD1zLkm1N\|Yh\|ryP	NXjqPW5VW0GQR1XS
LB2241-RCC	M1vpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvmTWM2OD1zLkm4NlMyKM7:TR?=	M2HERXNCVkeHUh?=
Ramos-2G6-4C10	M4LrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nBe2lEPTB;MT65PVQ6OyEQvF2=	NX6zWWg2W0GQR1XS
A101D	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW0TWM2OD1{LkKwN\|A{KM7:TR?=	Mne3V2FPT0WU
NCI-H446	NHnCVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\uVIRKSzVyPUKuNFQ2QTlizszN	M{L1bXNCVkeHUh?=
SBC-5	M3WwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TFU2lEPTB;Mj6wOlE1PyEQvF2=	M{nYbnNCVkeHUh?=
HOS	NWXXNm5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJwMEe2OVMh\|ryP	Ml3vV2FPT0WU
K5	NEDRO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPGTWM2OD1{LkC3PFEyKM7:TR?=	MYrTRW5ITVJ?
HLE	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHmwTnNKSzVyPUKuNFg2OjlizszN	MmLJV2FPT0WU
HSC-2	NYn4e5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXaTWM2OD1{LkGyPFk5KM7:TR?=	NX30fVJOW0GQR1XS
LCLC-97TM1	NWf0OJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJwMUS1PFMh\|ryP	M4HkfHNCVkeHUh?=
DMS-273	NYezZWd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoG4TWM2OD1{LkG0PFM4KM7:TR?=	MULTRW5ITVJ?
TE-8	MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHHd49KSzVyPUKuNVU4PjVizszN	M4XMbnNCVkeHUh?=
DSH1	M4PQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVuxUnBqUUN3ME2yMlE3Ozl6IN88US=>	MoHGV2FPT0WU
CAL-51	NF3TR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7Ubo1sUUN3ME2yMlE3Pjl7IN88US=>	MYjTRW5ITVJ?
IST-SL1	NVS2e\|dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3zeldKSzVyPUKuNVY5PDRizszN	NEe4XHdUSU6JRWK=
GCT	M1;Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv4S5dKSzVyPUKuNVc4PyEQvF2=	MV;TRW5ITVJ?
SW948	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrB[o41UUN3ME2yMlE5PDV4IN88US=>	MWLTRW5ITVJ?
NOMO-1	M{\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfDTWM2OD1{LkG5N\|E4KM7:TR?=	MkHRV2FPT0WU
C8166	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vP[2lEPTB;Mj6yNVM{PCEQvF2=	M{DqXXNCVkeHUh?=
OC-314	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJwMkOyOVkh\|ryP	NVv6PGdGW0GQR1XS
CAL-39	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPrTWM2OD1{LkKzOlI3KM7:TR?=	MkjqV2FPT0WU
MDA-MB-453	NUXkS\|IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJwMkSyO\|Uh\|ryP	MWfTRW5ITVJ?
A673	NIXaWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mln4TWM2OD1{LkK1PFYzKM7:TR?=	MVfTRW5ITVJ?
HTC-C3	NFfte45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknVTWM2OD1{LkK2PFUh\|ryP	NH\hU3FUSU6JRWK=
NCI-H1666	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfhcnRKSzVyPUKuNlgyOTFizszN	NYTGOXRPW0GQR1XS
PSN1	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvHTWM2OD1{LkK4PVE{KM7:TR?=	NUL5TINkW0GQR1XS
GI-1	NVHPRW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrOTWM2OD1{LkOwOVQ{KM7:TR?=	MVXTRW5ITVJ?
HuH-7	NYH4ZXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPXbVZwUUN3ME2yMlMxPjN5IN88US=>	NULpV2p6W0GQR1XS
JAR	MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr1Om46UUN3ME2yMlMyQTh5IN88US=>	M3PLbXNCVkeHUh?=
5637	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nCNmlEPTB;Mj6zNlEzQSEQvF2=	NFm1fGhUSU6JRWK=
GB-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLMTXNbUUN3ME2yMlMzOzN3IN88US=>	NHnRcVhUSU6JRWK=
KP-N-YS	NIXRSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7sTWM2OD1{LkOyOlE2KM7:TR?=	NFf3PYhUSU6JRWK=
OAW-42	NGLnboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z5RWlEPTB;Mj6zN\|QyPiEQvF2=	NGfRSJBUSU6JRWK=
8-MG-BA	M2qyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj1U3dQUUN3ME2yMlM{QTB4IN88US=>	NYHp[2JJW0GQR1XS
RH-18	NXLQXXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PWcGlEPTB;Mj6zOVAzOiEQvF2=	MknxV2FPT0WU
NCI-H1155	NFTHblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O0ZmlEPTB;Mj6zOlczPSEQvF2=	M2LnSXNCVkeHUh?=
NB17	NFXZOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zOPWlEPTB;Mj6zPFI1OyEQvF2=	MnnKV2FPT0WU
NCI-H1437	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7YSnFoUUN3ME2yMlQyQDd\|IN88US=>	MUnTRW5ITVJ?
SN12C	NWjBR\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rHPGlEPTB;Mj60N\|IyPCEQvF2=	M1PHSXNCVkeHUh?=
HSC-3	NGPwdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPaW3g3UUN3ME2yMlQ1PTB7IN88US=>	MU\TRW5ITVJ?
GAMG	NX3RNlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfXSog{UUN3ME2yMlQ1PTZzIN88US=>	NHvvSpFUSU6JRWK=
HT-1080	NGiwTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi5OIpIUUN3ME2yMlQ1QDZ2IN88US=>	MmLrV2FPT0WU
A549	NXfLfmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[2ZmlEPTB;Mj60OFg6OyEQvF2=	MkLjV2FPT0WU
KNS-62	M2\tVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[yTWM2OD1{LkS1NFYyKM7:TR?=	M2XQXnNCVkeHUh?=
YKG-1	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXXU3U2UUN3ME2yMlQ2PDN5IN88US=>	NVzSZ5VIW0GQR1XS
LU-134-A	M2\yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwNEewNFgh\|ryP	NH3abWdUSU6JRWK=
FADU	NEjXdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJwNEexOlIh\|ryP	NGizcnRUSU6JRWK=
TGBC11TKB	M1PPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrpTWM2OD1{LkS3NVc4KM7:TR?=	M3XL[HNCVkeHUh?=
HT-3	NGPOUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorGTWM2OD1{LkS5OVM2KM7:TR?=	NX\ITYppW0GQR1XS
NCI-H2170	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLZ[FhKSzVyPUKuOVA2PDlizszN	M1\hbnNCVkeHUh?=
Mo-T	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwNUC5Nlch\|ryP	NIroc3FUSU6JRWK=
CCRF-CEM	M2m1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJwNUOwOFMh\|ryP	NVzhNW1FW0GQR1XS
KU-19-19	M{TRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3NTWM2OD1{LkWzOVE{KM7:TR?=	M4H1SXNCVkeHUh?=
NCI-H1048	NWf1PGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTJwNUWwNlUh\|ryP	MnizV2FPT0WU
KOSC-2	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rKbmlEPTB;Mj61OlA4PiEQvF2=	M{T1fXNCVkeHUh?=
A431	M1XqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJwNU[zN\|Uh\|ryP	NVS5SoNMW0GQR1XS
COR-L23	NHG4[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITEdHhKSzVyPUKuOVg2PjZizszN	NInTUohUSU6JRWK=
MKN28	NWe0TmhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnMXHdKSzVyPUKuOVkxOzdizszN	MojLV2FPT0WU
22RV1	NXzOXHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFToVHJKSzVyPUKuOVkzPzRizszN	NXXmWlRjW0GQR1XS
ABC-1	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTvRodpUUN3ME2yMlYxPDZizszN	NVyybWtlW0GQR1XS
NCI-H2126	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;o[mlEPTB;Mj62NFk5PCEQvF2=	MlKyV2FPT0WU
DoTc2-4510	M3TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XFdGlEPTB;Mj62NlE5PSEQvF2=	M131VHNCVkeHUh?=
SCC-4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknYTWM2OD1{Lk[zNFEzKM7:TR?=	M3TDeXNCVkeHUh?=
NCI-H661	M2XvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnHcVQ1UUN3ME2yMlY1ODh3IN88US=>	MU\TRW5ITVJ?
RPMI-2650	NUD6WlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:3bXZpUUN3ME2yMlY1OTR\|IN88US=>	NEWzWHRUSU6JRWK=
NCI-H510A	NHu5XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr2TWM2OD1{Lk[0OFI3KM7:TR?=	NUKyZlhyW0GQR1XS
BPH-1	M{D5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTJwNkW4OUDPxE1?	MlW0V2FPT0WU
M14	NEPGdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4L6SmlEPTB;Mj62Olk6OyEQvF2=	MWfTRW5ITVJ?
G-402	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\iTWM2OD1{LkewOFUyKM7:TR?=	NEjvd2RUSU6JRWK=
AsPC-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHv6c21KSzVyPUKuO\|EyPyEQvF2=	MknpV2FPT0WU
NB12	NGPJVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJwN{G3NUDPxE1?	NHr2PHhUSU6JRWK=
SK-HEP-1	MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJwN{SzPVEh\|ryP	NFWyNGVUSU6JRWK=
U-266	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL3fIFVUUN3ME2yMlc4OTJzIN88US=>	MVzTRW5ITVJ?
AM-38	NWXIfJgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVOzN3BMUUN3ME2yMlc4OzV3IN88US=>	NWTaXlkxW0GQR1XS
PC-14	NWXY[WZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\U[WJKSzVyPUKuPFA2OSEQvF2=	M2rrOXNCVkeHUh?=
EGI-1	M1u5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXuTWM2OD1{LkixO\|Q{KM7:TR?=	NWnpXWRVW0GQR1XS
LS-411N	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jrbWlEPTB;Mj64NlM{KM7:TR?=	M33oOnNCVkeHUh?=
BFTC-905	MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELaem9KSzVyPUKuPFU2OjNizszN	NYDtb2JVW0GQR1XS
CaR-1	NVvYWnRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTJwOE[g{txO	MmG1V2FPT0WU
NCI-H292	M1y3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlyzTWM2OD1{Lki2OVk3KM7:TR?=	MYLTRW5ITVJ?
8305C	NIOzbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vpNmlEPTB;Mj64OlY1PSEQvF2=	MVXTRW5ITVJ?
SNU-449	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\HeGlEPTB;Mj64PVE5OiEQvF2=	NWrTR49YW0GQR1XS
LCLC-103H	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvINnA{UUN3ME2yMlkxPDN6IN88US=>	NETUfFBUSU6JRWK=
SW1573	NV7tXWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV34T2dOUUN3ME2yMlk3ODh{IN88US=>	NGDQVG9USU6JRWK=
MLMA	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonNTWM2OD1{Lkm2O\|E4KM7:TR?=	NGfjVXBUSU6JRWK=
NCI-H1355	M4TSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nqTGlEPTB;Mz6wNFc6PiEQvF2=	MYPTRW5ITVJ?
RMG-I	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHmTWM2OD1\|LkCyOVkzKM7:TR?=	MYLTRW5ITVJ?
BB65-RCC	NFPZPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPFO2ZKSzVyPUOuNFM{OTRizszN	M4HYWnNCVkeHUh?=
PC-3	Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoraTWM2OD1\|LkCzPFc1KM7:TR?=	MULTRW5ITVJ?
SF268	M3XQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTNwMES1NlMh\|ryP	M4nKdHNCVkeHUh?=
NCI-H810	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\aVXZKSzVyPUOuNFQ5OjNizszN	MVjTRW5ITVJ?
MEG-01	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoT5TWM2OD1\|LkC2NVY1KM7:TR?=	M2\0c3NCVkeHUh?=
SW13	NXLuOIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTNwMEe4OFch\|ryP	MWLTRW5ITVJ?
RH-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvsSYQzUUN3ME2zMlExOjd6IN88US=>	M1\aUXNCVkeHUh?=
GT3TKB	M{G2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;s[nVKSzVyPUOuNVEzQDNizszN	Ml7NV2FPT0WU
TK10	NWOy[453T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHOU4RKSzVyPUOuNVM4OjRizszN	MX7TRW5ITVJ?
T-24	NXnCe3NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmj1TWM2OD1\|LkG1NFch\|ryP	Mlr2V2FPT0WU
A498	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrLeZZNUUN3ME2zMlIxQDdzIN88US=>	Ml7mV2FPT0WU
GR-ST	NWXnfVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTNwMkKxN\|kh\|ryP	M3XjOXNCVkeHUh?=
LB2518-MEL	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HnbGlEPTB;Mz6yNlM6QCEQvF2=	M4Cy[nNCVkeHUh?=
T47D	M3fzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTNwMkO2Nlch\|ryP	NXzhUlN7W0GQR1XS
NCI-H1651	M2rYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rVXmlEPTB;Mz6yOFY1PCEQvF2=	NX\6RlA1W0GQR1XS
EC-GI-10	NXLW[nFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\N[IpKSzVyPUOuNlYyPTNizszN	M{nUbXNCVkeHUh?=
HT-29	NGPUfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTNwMk[2NVQh\|ryP	NFjwfm9USU6JRWK=
GI-ME-N	NWXCOlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vq[WlEPTB;Mz6yPVUyOSEQvF2=	Mmi5V2FPT0WU
SW756	NYTDfmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7xNVNKSzVyPUOuNlk3OjlizszN	MW\TRW5ITVJ?
RKO	NWi3bJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\pZW5qUUN3ME2zMlMxPzV5IN88US=>	NV;JVItnW0GQR1XS
NCI-H1563	M3v6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNwM{OwNVgh\|ryP	NIL1NJJUSU6JRWK=
DJM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDCTWM2OD1\|LkO3Olc1KM7:TR?=	NEDJVItUSU6JRWK=
L-428	M2DodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jzPGlEPTB;Mz60NFA1PSEQvF2=	M{K0e3NCVkeHUh?=
NCI-H2122	NF7yOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDrU2hKSzVyPUOuOFE{OTJizszN	M3XuPXNCVkeHUh?=
Ca-Ski	NIjTcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DpSmlEPTB;Mz60OVQ{KM7:TR?=	Mn\uV2FPT0WU
639-V	NU\IcnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTNwNE[wOVch\|ryP	MlPEV2FPT0WU
SW1116	NGm0W4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf6TWM2OD1\|LkS2NlY6KM7:TR?=	Mo\mV2FPT0WU
DMS-114	NYPTWWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrrc4NKSzVyPUOuOFcxPjZizszN	MmGyV2FPT0WU
MZ2-MEL	MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LveWlEPTB;Mz60O\|Y5OSEQvF2=	NGLNbWZUSU6JRWK=
COLO-829	M1nBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTNwNUCwO\|Mh\|ryP	MWDTRW5ITVJ?
J82	NFu2fFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorCTWM2OD1\|LkWwOVch\|ryP	NGG3T25USU6JRWK=
EW-13	M4\NO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjQbVlFUUN3ME2zMlUzPTFizszN	NYfuUFJMW0GQR1XS
RXF393	M4HoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjTWFFKSzVyPUOuOVMzQTRizszN	NVHTTpNPW0GQR1XS
CAL-62	NXzyfI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zuUmlEPTB;Mz61OFUyPCEQvF2=	MUfTRW5ITVJ?
OCUB-M	NFjXRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf2dmVKSzVyPUOuOVQ3PjVizszN	NXXQ[nZ2W0GQR1XS
BT-474	M13pOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHQXYFKSzVyPUOuOlM{OSEQvF2=	NF\KWodUSU6JRWK=
KYSE-180	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzBTWM2OD1\|Lk[zN\|czKM7:TR?=	M1zidHNCVkeHUh?=
NCI-H650	NVzaXnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3O1SWlEPTB;Mz62OFI5PyEQvF2=	MlGzV2FPT0WU
Detroit562	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fnWGlEPTB;Mz62OVAzOiEQvF2=	NH\iT\|RUSU6JRWK=
SW48	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moi5TWM2OD1\|Lk[1OlU4KM7:TR?=	M4q1Z3NCVkeHUh?=
KYSE-450	NF[5VG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjRXJNKSzVyPUOuOlg2QDJizszN	NXLxbYZCW0GQR1XS
KYSE-510	NGXw[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET4NFBKSzVyPUOuO\|IyQDFizszN	MWTTRW5ITVJ?
GP5d	NWjENHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rpZWlEPTB;Mz63Nlk2KM7:TR?=	M3PmPXNCVkeHUh?=
RPMI-7951	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTNwN{S3NlMh\|ryP	NFPXbFBUSU6JRWK=
Becker	NWXlW5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T1WGlEPTB;Mz63OVAyOiEQvF2=	NHfZfWJUSU6JRWK=
WM-115	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Sw[2lEPTB;Mz63PFE6PSEQvF2=	NVHyTWtkW0GQR1XS
G-401	M{\5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTNwN{mwPFUh\|ryP	MXzTRW5ITVJ?
PANC-08-13	NGLodXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L6RmlEPTB;Mz63PVYxOiEQvF2=	NHjjendUSU6JRWK=
SW982	NFTjT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;PcmlEPTB;Mz64NFU2OSEQvF2=	NUT4[I9MW0GQR1XS
D-263MG	M2L1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jOSmlEPTB;Mz64NlA2OSEQvF2=	NXLE[mRsW0GQR1XS
KM-H2	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFG2eJlKSzVyPUOuPFI3OjRizszN	NYOxXpp[W0GQR1XS
SK-MEL-3	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfjZW9sUUN3ME2zMlgzQDRzIN88US=>	MW\TRW5ITVJ?
NCI-H1581	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLQV5hKSzVyPUOuPFQ1QDhizszN	MVTTRW5ITVJ?
LS-123	NFW1ZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfPdnlKUUN3ME2zMlg4QTB7IN88US=>	MUHTRW5ITVJ?
CAKI-1	NYPFeph7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHIcXRDUUN3ME2zMlg6ODV{IN88US=>	MUfTRW5ITVJ?
MEL-JUSO	M1n2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrnTWM2OD1\|Lki5NVU{KM7:TR?=	NV3hNIVZW0GQR1XS
HCE-4	NE\NWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGn1RmlKSzVyPUOuPVE3PjNizszN	M4r5ZnNCVkeHUh?=
TE-10	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NImxTXpKSzVyPUOuPVIxOSEQvF2=	M2GySXNCVkeHUh?=
OVCAR-4	NHfqWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jxeGlEPTB;Mz65Nlg5QSEQvF2=	MWPTRW5ITVJ?
ETK-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTNwOUS2N\|Uh\|ryP	NILEN\|hUSU6JRWK=
A2780	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDLTWM2OD12LkC1PVY3KM7:TR?=	MXXTRW5ITVJ?
LU-65	NEXkfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTRwMEe2N\|Mh\|ryP	NXnlcJdKW0GQR1XS
BHY	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXKZlJSUUN3ME20MlEzPDl3IN88US=>	Mn7SV2FPT0WU
COR-L105	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTRwMUOwOVEh\|ryP	M4jVd3NCVkeHUh?=
CAL-12T	NVjs[YZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTje5RxUUN3ME20MlE{OTB\|IN88US=>	MnntV2FPT0WU
SCH	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmO1TWM2OD12LkG1O\|Q{KM7:TR?=	MnTLV2FPT0WU
CW-2	NFLacXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELuZo9KSzVyPUSuNVkxODFizszN	MnHDV2FPT0WU
HCC1806	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;XTWM2OD12LkKwN\|EzKM7:TR?=	NHrvTXVUSU6JRWK=
KP-N-YN	M1z3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK4TWM2OD12LkKwPVI4KM7:TR?=	Ml7sV2FPT0WU
T98G	NVLrOWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTRwMkKxOVch\|ryP	MmfrV2FPT0WU
CAL-54	NHn1epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LyeWlEPTB;ND6yNlM5OSEQvF2=	M{n6XnNCVkeHUh?=
CAL-33	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTRwMkOwOlQh\|ryP	NGf3RYFUSU6JRWK=
SNU-C2B	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3MTWM2OD12LkK0O\|Y6KM7:TR?=	NIXZZVFUSU6JRWK=
NUGC-3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnkdolsUUN3ME20MlI2PTB3IN88US=>	NWfDNWJUW0GQR1XS
DOK	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi0R2FKSzVyPUSuNlY2QTNizszN	M2jGc3NCVkeHUh?=
MMAC-SF	NXW4[YlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HlWWlEPTB;ND6yOlg2QSEQvF2=	NGn3eFVUSU6JRWK=
KYSE-70	NIHyZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTRwMkmzOEDPxE1?	MYLTRW5ITVJ?
A204	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3xcFRKSzVyPUSuN\|U5ODNizszN	MonHV2FPT0WU
SCC-25	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe5SZZKSzVyPUSuN\|U5OTlizszN	Ml[3V2FPT0WU
EPLC-272H	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\NNWVKSzVyPUSuN\|g6PSEQvF2=	NYDIVVZpW0GQR1XS
CAL-120	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTRwM{i5PVIh\|ryP	MmTMV2FPT0WU
LS-513	NIjmTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXPTWM2OD12LkSyNVk5KM7:TR?=	NYK5[JFEW0GQR1XS
CAPAN-1	NFXsVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WxTWlEPTB;ND60NlM5OiEQvF2=	MV\TRW5ITVJ?
ESS-1	NXPxNJJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjze4hKSzVyPUSuOFI4OjRizszN	NULIS5FrW0GQR1XS
GMS-10	NEOxNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\BTWM2OD12LkSyPFE6KM7:TR?=	MXXTRW5ITVJ?
NCI-N87	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLpeI82UUN3ME20MlUxQDZ6IN88US=>	NIKw[IZUSU6JRWK=
HMV-II	NY\KSnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIK5XVJKSzVyPUSuOVE4OyEQvF2=	NHPnZ2FUSU6JRWK=
COLO-741	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvrOpRKSzVyPUSuOVU6QTRizszN	M1Syb3NCVkeHUh?=
MKN45	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTRwNUe3N\|Ih\|ryP	NXHLNJlsW0GQR1XS
OAW-28	NVezW4VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[wPWJiUUN3ME20MlU5Ozl6IN88US=>	M4fVVHNCVkeHUh?=
OCI-AML2	NHHRWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjwbFR[UUN3ME20MlY2OjN6IN88US=>	Ml7GV2FPT0WU
MDA-MB-231	NH75W2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHkV3RKSzVyPUSuO\|AzPDNizszN	M4nCNHNCVkeHUh?=
NCI-H1648	M{nRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTTeZRbUUN3ME20MlczOjd\|IN88US=>	NEm5UG5USU6JRWK=
NCI-H1792	NV;wbZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXNO4NKSzVyPUSuO\|YyODdizszN	M1zoT3NCVkeHUh?=
GCIY	NUK5OYw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTRwN{e0NlQh\|ryP	M1HBdnNCVkeHUh?=
Hs-578-T	NHXNeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XY[mlEPTB;ND63O\|Y2PSEQvF2=	MVXTRW5ITVJ?
SW962	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTRwN{iwNVEh\|ryP	NH24O\|FUSU6JRWK=
NCI-H630	NWX0TIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnrT2JGUUN3ME20Mlc5ODhzIN88US=>	NFTUUldUSU6JRWK=
786-0	NEDXZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPBe5RPUUN3ME20Mlc5Pzd\|IN88US=>	NIHEW5JUSU6JRWK=
FTC-133	NHXPb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkWzTWM2OD12Lke5NlY{KM7:TR?=	M{DiV3NCVkeHUh?=
BT-20	M{fuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XQPGlEPTB;ND63PVQzQSEQvF2=	NX60d2VqW0GQR1XS
Mewo	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnzfJVvUUN3ME20MlgyPzR5IN88US=>	MXfTRW5ITVJ?
SW780	MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKzbWo1UUN3ME20Mlg2PzZ4IN88US=>	MV7TRW5ITVJ?
OE33	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXWOW1KSzVyPUSuPFc4OTNizszN	MWDTRW5ITVJ?
HCC1569	M2G2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTRwOEi0OVgh\|ryP	NGrPd3RUSU6JRWK=
TE-6	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXWwdJFvUUN3ME20Mlk{QTd5IN88US=>	MX3TRW5ITVJ?
SK-N-FI	M1ziNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjwOlFUUUN3ME20Mlk1PDJzIN88US=>	NEjrV5lUSU6JRWK=
PANC-03-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTlTWM2OD12Lkm5PVYzKM7:TR?=	M4\0bnNCVkeHUh?=
MCF7	NWHwUI1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfUTWM2OD13LkCwO\|M5KM7:TR?=	MWfTRW5ITVJ?
UACC-257	NGjK[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3Db5NKSzVyPUWuNFI5PDVizszN	M{LibHNCVkeHUh?=
SW1088	MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTVwMEK5OFQh\|ryP	MYjTRW5ITVJ?
A704	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NISx[IRKSzVyPUWuNFMxPiEQvF2=	NX3KbVhKW0GQR1XS
A2058	M4fSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\RTWM2OD13LkC1PVA5KM7:TR?=	MkfWV2FPT0WU
Calu-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DnRmlEPTB;NT6wOlQ2OiEQvF2=	M1TnXXNCVkeHUh?=
RERF-LC-MS	NFS5UohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnrTWM2OD13LkC2PVA{KM7:TR?=	MlWyV2FPT0WU
AU565	NVfETmtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTVwMEm3NFIh\|ryP	Mn32V2FPT0WU
DMS-79	NXnv[Xd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7oN\|hKSzVyPUWuNVM5QDNizszN	MUHTRW5ITVJ?
DK-MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1q4S2lEPTB;NT6xPFQ{QCEQvF2=	NEXuTllUSU6JRWK=
HuCCT1	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jRWGlEPTB;NT6yN\|g2PiEQvF2=	Mn\KV2FPT0WU
HT-144	NIPPR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4CwfWlEPTB;NT6yOFk5PyEQvF2=	MX3TRW5ITVJ?
M059J	NFnYcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTVwMkW3OkDPxE1?	NVjRdZB4W0GQR1XS
COLO-792	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTVwMk[zOVYh\|ryP	M3y0eHNCVkeHUh?=
SF539	NGqzU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXQSIM4UUN3ME21MlI3PjN{IN88US=>	Ml7uV2FPT0WU
SK-UT-1	NEn3ZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfHUWpKSzVyPUWuNlc4PTFizszN	MXfTRW5ITVJ?
NCI-H1703	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3tO3VIUUN3ME21MlM2QDJ4IN88US=>	NUTYZlZ3W0GQR1XS
SW837	NYXsWmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2H0SmlEPTB;NT6zO\|g4QCEQvF2=	NIi2d4JUSU6JRWK=
U251	NFe3bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\WOGlEPTB;NT6zPVA6PiEQvF2=	MmraV2FPT0WU
SW1710	M1z6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTWfld2UUN3ME21MlQyPTV2IN88US=>	NGTuR45USU6JRWK=
NCI-H1299	M1;1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1KwXmlEPTB;NT60OlM{PSEQvF2=	NVX2XJZsW0GQR1XS
RVH-421	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jFUGlEPTB;NT60PVkxQCEQvF2=	NW\JWpJMW0GQR1XS
UM-UC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rpeWlEPTB;NT62NlY2OSEQvF2=	MkDGV2FPT0WU
MDA-MB-175-VII	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3i5b2lEPTB;NT62OFA1OSEQvF2=	M4XPUnNCVkeHUh?=
KYSE-270	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LiSWlEPTB;NT62OlA{OSEQvF2=	NYHMOnhMW0GQR1XS
COLO-668	NGj2doZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTVwN{GzNkDPxE1?	MlLNV2FPT0WU
LN-405	NWO3eGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\LXW9KSzVyPUWuO\|MxQDVizszN	MkG0V2FPT0WU
HT-1376	NITLcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTVwN{iwOVIh\|ryP	NFLoZY1USU6JRWK=
769-P	NF62O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\DWWVKSzVyPUWuPFY4OThizszN	M3jQcnNCVkeHUh?=
HuP-T3	MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTVwOEi2O\|ch\|ryP	M3WxWHNCVkeHUh?=
MDA-MB-415	Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfYe\|JMUUN3ME21MlkzOTN7IN88US=>	M4fWVXNCVkeHUh?=
MKN7	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTVwOUi4JO69VQ>?	NF3GXoRUSU6JRWK=
KS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3rT3lKSzVyPUWuPVg5OzZizszN	M3[zbnNCVkeHUh?=
647-V	M{TEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTVwOUmxOFgh\|ryP	MXXTRW5ITVJ?
COLO-679	NVzzfphDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13iOWlEPTB;Nj6wNFI2PSEQvF2=	MkfDV2FPT0WU
AN3-CA	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHGOnV4UUN3ME22MlA{PDRzIN88US=>	MULTRW5ITVJ?
C32	M3;yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTZwMUOwN\|Qh\|ryP	M2jINnNCVkeHUh?=
KM12	NEXHU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fHXWlEPTB;Nj6yOFA6QSEQvF2=	MXXTRW5ITVJ?
KINGS-1	NVG2O2poT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrPeHZqUUN3ME22MlI3OTV{IN88US=>	NXPOXng1W0GQR1XS
KYSE-410	NWT4eZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7jUFdKSzVyPU[uN\|A3PDVizszN	MnXHV2FPT0WU
HPAF-II	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\JeI04UUN3ME22MlM2PDhizszN	NY\yVlhuW0GQR1XS
LAN-6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLCOFA1UUN3ME22MlQ6PjNzIN88US=>	M1fRTHNCVkeHUh?=
LU-99A	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXJTWM2OD14LkW1PVg6KM7:TR?=	MWnTRW5ITVJ?
SJSA-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G3NGlEPTB;Nj61OlM1PyEQvF2=	MYXTRW5ITVJ?
MSTO-211H	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPxTWM2OD14LkeyNlM{KM7:TR?=	NWPIPW9FW0GQR1XS
SW900	M1vBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[zbmlEPTB;Nj63OlIzOSEQvF2=	M373S3NCVkeHUh?=
LNCaP-Clone-FGC	M2\EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nPemlEPTB;Nj64NFQxOyEQvF2=	M4jSfnNCVkeHUh?=
OMC-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPHTWM2OD14Lki1OFAzKM7:TR?=	M37zc3NCVkeHUh?=
IST-MEL1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4H6RmlEPTB;Nj64PVY3QSEQvF2=	M3zRW3NCVkeHUh?=
TE-9	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\Vco9KSzVyPU[uPFk5PDdizszN	Mn3sV2FPT0WU
NCI-H2030	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPKVGtxUUN3ME22MlkyOjJ4IN88US=>	NFO4S\|BUSU6JRWK=
BFTC-909	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LxTmlEPTB;Nz6wNFY1OSEQvF2=	NXjCTWt6W0GQR1XS
NCI-SNU-5	NG[zTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j1ZmlEPTB;Nz6wNlE2QSEQvF2=	M2\neXNCVkeHUh?=
TE-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XkeGlEPTB;Nz6wNlg5OSEQvF2=	M3XYXHNCVkeHUh?=
SK-MES-1	NH7WU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n5cWlEPTB;Nz6wOVQzPyEQvF2=	M4XyOnNCVkeHUh?=
SHP-77	NVvQNW1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSyclM6UUN3ME23MlE{QTV{IN88US=>	NHjZbFlUSU6JRWK=
NCI-H1623	M3TvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7nXJpKSzVyPUeuNVQxPzJizszN	NYq1bZFPW0GQR1XS
TE-11	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlK1TWM2OD15LkG1NVg1KM7:TR?=	MkDUV2FPT0WU
EKVX	NFLMelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17rXmlEPTB;Nz6xPVI3PyEQvF2=	M33qbHNCVkeHUh?=
OVCAR-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[5bWlEPTB;Nz6yNVE{OyEQvF2=	M3zRRnNCVkeHUh?=
C3A	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDPTWM2OD15LkO0OVIh\|ryP	MYTTRW5ITVJ?
CFPAC-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD1TWM2OD15LkO2NlIzKM7:TR?=	M1j1SXNCVkeHUh?=
MG-63	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LvV2lEPTB;Nz60NVg1QSEQvF2=	NIPyeWhUSU6JRWK=
KYSE-140	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTdwNESwOlEh\|ryP	M4fsVnNCVkeHUh?=
MPP-89	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3LcWxHUUN3ME23MlU6PzJ7IN88US=>	NEi1NG9USU6JRWK=
COLO-824	M2PpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIeyc5ZKSzVyPUeuO\|I5PjNizszN	MX7TRW5ITVJ?
SiHa	NWrSVWdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S0OWlEPTB;Nz64N\|cxPyEQvF2=	M3zRWXNCVkeHUh?=
SNU-387	NYnJ[IRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfUNW5DUUN3ME23Mlg2OzR5IN88US=>	NXnwU3ZFW0GQR1XS
A172	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjZUGhKSzVyPUeuPFYyPzJizszN	M3L2RXNCVkeHUh?=
COLO-680N	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDBbnV3UUN3ME23MlkyPzNizszN	MoCwV2FPT0WU
HCC1395	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS2boxLUUN3ME24MlA2PDV{IN88US=>	NWiwdm1WW0GQR1XS
NCI-H28	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jMR2lEPTB;OD6wOVk3OyEQvF2=	M{PCdnNCVkeHUh?=
LC-2-ad	M4X2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7vNGNKSzVyPUiuNlE6OzdizszN	MVLTRW5ITVJ?
S-117	M3PUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH2TWM2OD16LkK1N\|U{KM7:TR?=	MoLFV2FPT0WU
NCI-H1838	NVP2fppET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTMTW0{UUN3ME24MlI2PzhzIN88US=>	NEi2ZWxUSU6JRWK=
PANC-10-05	NIDWNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7lR3NKSzVyPUiuN\|cxPDdizszN	NFv5U45USU6JRWK=
KALS-1	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRThwNUC5Nlgh\|ryP	M4jhS3NCVkeHUh?=
LS-1034	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;WNIg1UUN3ME24MlU4PDN5IN88US=>	M{i5e3NCVkeHUh?=
TGBC1TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEK2e5NKSzVyPUiuO\|M2OzVizszN	NWLo[491W0GQR1XS
OE19	M2rUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\POWFlUUN3ME24Mlc3OjZ{IN88US=>	MX7TRW5ITVJ?
D-502MG	NVjs[4tST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3oVY9KSzVyPUiuO\|Y6QTRizszN	M3\uZnNCVkeHUh?=
JEG-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRThwN{i2NVgh\|ryP	NEC1Wm9USU6JRWK=
DBTRG-05MG	M360UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\UTWM2OD16Lki3OVY2KM7:TR?=	MmH0V2FPT0WU
ME-180	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTlwME[3NlUh\|ryP	MkOwV2FPT0WU
NCI-H1573	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XpR2lEPTB;OT6xNFU{OiEQvF2=	NVqx[lgxW0GQR1XS
HCC2998	M4jtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTlwMUO2PFEh\|ryP	NEDoR5lUSU6JRWK=
ACHN	NHjodVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlf0TWM2OD17LkK0PVc2KM7:TR?=	NU\1WFR3W0GQR1XS
D-392MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jTVGlEPTB;OT6yOVcyPSEQvF2=	MojFV2FPT0WU
no-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvPTlRKSzVyPUmuNlYxOjhizszN	NIPXXGRUSU6JRWK=
KLE	NHOwPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTlwM{KyN\|Ih\|ryP	NVKz[oo4W0GQR1XS
Calu-6	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLWfXhKSzVyPUmuN\|c2OjhizszN	MV;TRW5ITVJ?
LB831-BLC	M4\EXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjDVphDUUN3ME25MlQ2OTdzIN88US=>	NFvhTGNUSU6JRWK=
SW684	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ywWWlEPTB;OT60OlEyPiEQvF2=	MkLlV2FPT0WU
SH-4	NILFTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPuXYJKSzVyPUmuOFk{PjRizszN	MYjTRW5ITVJ?
IST-MES1	NF3tXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTlwNUG2OFQh\|ryP	MlTPV2FPT0WU
Saos-2	M3H0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXnTWM2OD17LkWyNVk2KM7:TR?=	NGPjT3lUSU6JRWK=
NCI-H2087	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTlwNkezOVIh\|ryP	Mn\QV2FPT0WU
SCC-9	NWfySVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[zTWM2OD17LkexPFE3KM7:TR?=	NUfqU4hLW0GQR1XS
MFE-280	NX7iVpczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHmdHRKSzVyPUmuO\|I4QDVizszN	M2m0[nNCVkeHUh?=
BEN	M3LLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnuwTWM2OD17LkiyNVU6KM7:TR?=	NIjsT2RUSU6JRWK=
CP50-MEL-B	NEfoTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPDU\|NnUUN3ME25MlkzPDN{IN88US=>	MlzFV2FPT0WU
SK-MEL-28	NHHKVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL4eIZHUUN3ME2xNE4xOTl\|IN88US=>	NUfDN5NJW0GQR1XS
NCI-H2452	M3HNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\XV21KSzVyPUGwMlE3KM7:TR?=	MY\TRW5ITVJ?
NCI-H1395	NV;vV4xmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfQSXdyUUN3ME2xNE4yPzhizszN	Mnj0V2FPT0WU
NCI-H2052	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPXRYpKSzVyPUGwMlE5QDJizszN	NIDvR49USU6JRWK=
A375	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\tTVlKSzVyPUGwMlI1PTJizszN	M4HyWHNCVkeHUh?=
HCC38	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFyLkOyNkDPxE1?	M2CzN3NCVkeHUh?=
LK-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfxTmgzUUN3ME2xNE41OjB6IN88US=>	MofPV2FPT0WU
SF126	M{f4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7JTWM2OD1zMD60O\|I4KM7:TR?=	MkjyV2FPT0WU
SK-MEL-1	NW\ZN2NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGG4[I9KSzVyPUGwMlc5OzhizszN	NIPNPVlUSU6JRWK=
ACN	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vMUGlEPTB;MUCuPFY4QSEQvF2=	NFvVNm1USU6JRWK=
BB30-HNC	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PZZWlEPTB;MUCuPFcyOSEQvF2=	Ml2wV2FPT0WU
NCI-H747	NGq1PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTFyLki3OFYh\|ryP	M4LWVnNCVkeHUh?=
KYSE-150	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDHXWJrUUN3ME2xNU4xOzh5IN88US=>	NEDkUopUSU6JRWK=
D-247MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLPTWM2OD1zMT6xNFA6KM7:TR?=	M3XrenNCVkeHUh?=
BxPC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFzLkO3OFch\|ryP	NV7NcGZ[W0GQR1XS
SK-MEL-30	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHDfpVKSzVyPUGxMlQxPzlizszN	M2TLPXNCVkeHUh?=
CAS-1	M3TJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXCRZl5UUN3ME2xNU41OTB7IN88US=>	MXjTRW5ITVJ?
no-10	NHPkd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPPTWM2OD1zMj6xNlE4KM7:TR?=	NWHod2dsW0GQR1XS
NCI-H2405	NIDQS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWCxXoJDUUN3ME2xNk4zODN4IN88US=>	M3rHNHNCVkeHUh?=
KGN	M4myUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPvV5ZKSzVyPUGyMlI6ODFizszN	MX3TRW5ITVJ?
BB49-HNC	NETubXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIGzO4lKSzVyPUGyMlM6PTZizszN	MkDKV2FPT0WU
NCI-H1693	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPxeWJJUUN3ME2xNk42QDF4IN88US=>	MUnTRW5ITVJ?
RO82-W-1	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrETWM2OD1zMz6wOlQ6KM7:TR?=	MYjTRW5ITVJ?
CAL-85-1	NVPPU4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPqTWM2OD1zMz60N\|k6KM7:TR?=	M2n0dHNCVkeHUh?=
H-EMC-SS	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmWzTWM2OD1zMz65NVA1KM7:TR?=	M{Hrb3NCVkeHUh?=
SW1783	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS5O25RUUN3ME2xOE4zOzlzIN88US=>	NHHFVpRUSU6JRWK=
LB771-HNC	NVLnZnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTF2LkSxPUDPxE1?	M{XNcnNCVkeHUh?=
HCC70	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUX4VHNXUUN3ME2xOE41OjN\|IN88US=>	MoC1V2FPT0WU
KNS-81-FD	NXLFWVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjRcJlKSzVyPUG0MlcxPDVizszN	NWnifHVuW0GQR1XS
KYSE-520	NVnoU5QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jiNWlEPTB;MUSuPVI4KM7:TR?=	MknBV2FPT0WU
TGBC24TKB	MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzKTWM2OD1zND65OVM6KM7:TR?=	NYDab\|FkW0GQR1XS
SNB75	NFPsWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XEbWlEPTB;MUWuNFczQSEQvF2=	NXPwZZFsW0GQR1XS
SW872	NHHiTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DhSWlEPTB;MUWuNlIyQCEQvF2=	M3fCe3NCVkeHUh?=
U031	NVnhdJFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHCOZFKSzVyPUG1MlgxOjhizszN	NVPvcI1pW0GQR1XS
ChaGo-K-1	NI\HWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXe5dYl5UUN3ME2xOU45OzV7IN88US=>	NInB[4lUSU6JRWK=
NCI-H441	NF3hPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDON2hYUUN3ME2xOk4xODN7IN88US=>	M4XUTHNCVkeHUh?=
TE-12	NGX5XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mke0TWM2OD1zNj6xPFc{KM7:TR?=	NHWwZ49USU6JRWK=
NCI-H1755	NX\vUXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnrPJhPUUN3ME2xOk42PzNizszN	MnzlV2FPT0WU
KNS-42	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGwdIlKSzVyPUG2MlY2QDlizszN	NGLiVWJUSU6JRWK=
SK-PN-DW	M{DKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rScmlEPTB;MUeuOFIxOSEQvF2=	NIHuXGVUSU6JRWK=
NCI-H226	NHP0RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXKRW9KSzVyPUG3Mlk{PDVizszN	NVjFV4tjW0GQR1XS
K-562	M1HibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF6Lk[zNVch\|ryP	NXPOOG1{W0GQR1XS
A388	NU\4cms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3xRpJKSzVyPUG5MlA{ODNizszN	Mlu0V2FPT0WU
ZR-75-30	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTF7LkC5Olgh\|ryP	MYPTRW5ITVJ?
LU-135	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTFTWM2OD1zOT6yOlM3KM7:TR?=	MnH1V2FPT0WU
NCI-H2029	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTDXGNKSzVyPUG5MlYxOjFizszN	NYXQPYtNW0GQR1XS
HT-1197	NFrLPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG2TWM2OD1zOT65NlI4KM7:TR?=	NIjjN\|lUSU6JRWK=
IGR-1	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37wdWlEPTB;MkCuN\|EyPyEQvF2=	MVXTRW5ITVJ?
U-87-MG	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTJyLk[0NVMh\|ryP	Ml20V2FPT0WU
NCI-H1304	M1zld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jGTmlEPTB;MkCuO\|UxOSEQvF2=	M{L4S3NCVkeHUh?=
RCC10RGB	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrJdnJKSzVyPUKxMlI5OjlizszN	NGexOVVUSU6JRWK=
NCI-H520	NUCxS5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TPPGlEPTB;MkKuO\|YyOSEQvF2=	MlfVV2FPT0WU
SK-LU-1	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojHTWM2OD1{Mz6wO\|E5KM7:TR?=	M363U3NCVkeHUh?=
UACC-893	NGDYb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M12wXGlEPTB;MkOuNVA{QCEQvF2=	NGewfm9USU6JRWK=
NCI-H2347	M4Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILxOJlKSzVyPUKzMlI3PzRizszN	M1LufXNCVkeHUh?=
U-118-MG	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTJ\|LkeyNVch\|ryP	NI\u[4dUSU6JRWK=
NCI-H596	M{TGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HFR2lEPTB;MkOuPVA2PSEQvF2=	NEXJc4VUSU6JRWK=
MZ1-PC	NHXCcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnDOWFvUUN3ME2yOE43PzV7IN88US=>	NELIOJVUSU6JRWK=
SW1417	NXewRm02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fhbGlEPTB;MkWuNlQ6QCEQvF2=	MXLTRW5ITVJ?
NCI-H82	M3fEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TVbWlEPTB;Mk[uOFI5QCEQvF2=	MWjTRW5ITVJ?
COLO-678	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fLV2lEPTB;MkeuOFkyQSEQvF2=	M{HXWHNCVkeHUh?=
KURAMOCHI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzQTWM2OD1{OD6xNlYh\|ryP	MlrkV2FPT0WU
NCI-H1650	NELjXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jBVWlEPTB;M{CuNVkzPCEQvF2=	NXXTSIlQW0GQR1XS
HCC1954	NF22dIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K2eGlEPTB;M{GuN\|Y3PiEQvF2=	Mn[0V2FPT0WU
GAK	M4\zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7jXWxKSzVyPUOyMlI3OTZizszN	MWTTRW5ITVJ?
YAPC	NWfGTpVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTN\|Lke2OFgh\|ryP	NInj[pBUSU6JRWK=
NCI-H2228	NX\XOoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofwTWM2OD1\|ND6zOlA2KM7:TR?=	NFLoOmhUSU6JRWK=
VMRC-RCZ	M2\xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjJOYx5UUN3ME2zOk4{ODJ{IN88US=>	NILzcoFUSU6JRWK=
NMC-G1	M4D1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzETWM2OD1\|Nz6wOVI6KM7:TR?=	NYLLNnFIW0GQR1XS
D-336MG	NUKxfnVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInwXFZKSzVyPUSxMlg1PDJizszN	MYHTRW5ITVJ?
UACC-62	NF[1PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXG[VFKSzVyPUSyMlU2ODVizszN	M1HvdHNCVkeHUh?=
C-33-A	NFXyUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;zS2lEPTB;NEWuN\|I2PiEQvF2=	MWrTRW5ITVJ?
HCC1937	NVnpV4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTNTWM2OD12Nz6xPVU5KM7:TR?=	M4K1Z3NCVkeHUh?=
HDLM-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\MTWM2OD12Nz6yNlg4KM7:TR?=	MlnJV2FPT0WU
NCI-H727	NVq3SYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LyT2lEPTB;NEeuNlQ2OSEQvF2=	MkLzV2FPT0WU
NY	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXjTYlMUUN3ME20PU4{QTB6IN88US=>	NUjnW\|FzW0GQR1XS
NCI-H2291	M2\nZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlizTWM2OD12OT64N\|AyKM7:TR?=	M{L2dHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	MK0683
Smiles	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)